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John Spivack
This dissertation proposes a method to explore a dose response curve adaptively, allowing
new doses to be inserted into the trial after initial results have been observed. The context
of our work is adaptive seamless Phase II/III trials and a systematic Limb-Leaf Design is
developed. In a case of a nonmonotonic dose response curve where the desired level of effect
exists in only a narrow dose range, a simulated comparison between a Limb-Leaf Design
and a standard (Thall, Simon, and Ellenberg or TSE-type) adaptive seamless design shows
a savings in risk adjusted expected sample size of up to 25%.
Chapter 1 is a review of concepts and particular adaptive seamless designs of interest.
Chapter 2 proposes dose addition in adaptive seamless designs and identifies ALS research
as an area of application. Chapter 3 develops dose addition as an application of existing
methodology. Chapter 4 identifies shortcomings of this approach and proposes a new Hori-
zontal Test as the basis for the Limb-Leaf Design. Chapter 5 supports the development of
the Limb-Leaf Design with several theoretical observations. The Limb-Leaf Design is devel-
oped in Chapters 6 and 7. Chapter 8 shows a comparison of the Limb-Leaf Design with a
TSE-type adaptive seamless design by simulation. Future work is suggested in Chapter 9.
Key words: Horizontal Test, adaptive design, dose response curve, nonmonotonicity,
closed testing principle, dose addition.
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The traditional process of drug development consists of four (or more) phases: Phase 1, to
find which doses can be tolerated, particularly the maximum tolerated dose (MTD); Phase
2, to determine the biological activity and adverse event rates of the tolerated doses; Phase
3, to determine efficacy of a selected dose; and Phase 4, after regulatory approval of the
drug, as a review of safety and other long term results. Traditionally, Phase 3 is run and
analyzed independently of Phase 2 and the information on Phase 2 results is not used in the
final determination of efficacy.
One method of reducing the large costs in time, money, and patient exposure of this
process is to combine these phases together and to eliminate the gaps and delays between
them. It is often possible to meet the objectives of Phases 2 and 3 within one less costly,
combined study and to replace the effort and delay of organizing two studies with that of
organizing one. In general, a seamless design is a design that combines the objectives of
multiple phases of the development process into a single trial.
New issues emerge in the design, conduct, and final inference of such a study. The Phase
22 data on efficacy and adverse event rates will not be available at the start of the study. Since
this information is necessary to complete the design of a Phase 3 study with adequate power
and control of the type I error probability, the latter part of the trial will have to be allowed
to change based on data from the earlier part. An adaptive design is one that allows the
modification of some aspect of the trial based on data that emerges during the trial. Since
there are differences in terminology among authors, we accept the definition used by Jennison
[14] under which designs that allow treatment selection; sample size reestimation; changes of
endpoints, test statistics, or subpopulations; or other modifications, are considered adaptive.
Adaptive designs may be rigid, with selection rules prespecified; partially flexible, allowing
adaptations within a given framework; or totally flexible. The term “rigid adaptive design”
does not involve any contradiction. In all cases, however, the changes must be “adaptive by
design” rather than post hoc in order to preserve statistical validity.
An adaptive seamless design is one that: (1) combines the objectives of different stages,
(2) allows modification of the trial based on emerging data, and (3) is inferentially seamless
in the sense that the final analysis combines data from before and after any adaptation. A
basic example of an adaptive seamless design combining Phases 2 and 3 would have two
stages, the first for learning, the second for confirming. Several patient cohorts, defined
by some factor such as dose level or subpopulation would be studied during the learning
stage. At an interim analysis a selection decision would be made about which cohorts would
be worth further study with additional recruitment in the second stage. After the second,
confirmatory stage, the results of both stages would be combined in a way that allows a
pre-specified type I error rate and power to be achieved. Effect estimates and confidence
intervals should be derived although the process is more involved in this case than in the
case of a single independent Phase 3 trial.
The benefits and limitations of adaptive designs have been well discussed. The benefits
are attractive: to speed up the process of drug development, to reduce organizational effort,
and to allow the data from earlier stages to contribute to the final analysis. However, there
3are two major kinds of criticisms. From a practical point of view, adaptive seamless designs
are well suited to cases where the time needed to reach the endpoint which is the basis for
adaptation is not too long relative to the recruitment rate of the study. During the time
prior to the adaptation, there will be a period during which some of the patients have not
yet been followed long enough to have been evaluated for the endpoint being used for the
modification. If the time to reach this needed endpoint is long relative to the recruitment
rate of the study then many patients will wind up being randomized to treatment arms that
are not desired and will not contribute to the final analysis. Attempting to pause recruitment
would disrupt the study, waste time, and lose many of the benefits of the adaptive design.
This objection can be overcome in many circumstances by basing the adaptation decision
on well chosen early outcomes or surrogate markers. Maca et al. [28] explain that only a
well understood early outcome or, ideally, a surrogate should be used.
The theoretical criticism of adaptive designs is that the tests involved may not depend
on sufficient statistics and so do not achieve the maximum theoretical efficiency. Such a
departure from the theoretical ideal could counteract the design’s intended benefit of being
able to draw extra strength from the use Phase II data. This criticism is most relevant to
totally flexible designs and to specific inefficient adaptations such as the (unscheduled) rescue
of underpowered studies or sample size reestimation based upon an estimate of treatment
effect. Jennison [14] and Liu and Anderson [1] among others defend the usefulness and
efficiency of adaptive designs, particularly in the rigid or partially flexible forms.
A further issue is that the treatment selection and possibility of early stopping in an
adaptive seamless trial leads to statistical bias in the maximum likelihood estimate of the
selected treatment’s effect, and also to inaccurate coverage of the associated confidence in-
terval. However, appropriate modifications have been developed. A confidence set can be
derived through the duality of hypothesis tests and confidence intervals, leading to the “re-
peated” confidence interval that is strictly conservative. Alternatively, a confidence interval
can be constructed using a stagewise ordering of the sample space as described by Brannath,
4Posch, and Bauer [7]. The bias of maximum likelihood estimates has been evaluated, and
this allows the use of bias-adjusted estimates. The statistical properties of point estimates
and simultaneous confidence intervals have also been investigated by Stallard and Todd [40].
The origins of adaptive seamless designs are in early work on fully sequential identification
and ranking from the 1960’s. The aim of these procedures was to select the treatment with
the highest mean or rate under a requirement on the probability of correct selection under
a specified alternative. Early elimination of weak treatments and adaptive allocation of
subjects to treatment arms were considered by Bechhofer, Kiefer, and Sobel among others
[5].
To overcome the need for continuous monitoring, the first two-stage design was proposed
by Thall, Simon, and Ellenberg [42]. Details are given in Section 1.2. In this design, the first
stage is used to select the best of several candidate treatments and the second stage focuses
only on the selected treatment. Both stages include a control arm and the data from both
stages are pooled for the final inference. This design applies only to binary outcomes. For
survival comparisons, a two stage screening design was proposed by Schaid, Wieand, and
Therneau [33].
A generalization that includes multiple stages and the use of a test based on the score
statistic was proposed by Stallard and Todd [38]. As explained in Section 1.2, the score based
method accommodates a general endpoint, which, for instance, could be normal, binary,
ordinal or a time to an event. Other designs have considered all pairwise comparisons with
the control, such as the group sequential design of Follman, Proschan, and Geller [9]. An
early endpoint for treatment selection and a primary endpoint for confirmation were used by
Stallard and Todd in [39] Another route for the development of adaptive seamless designs
has been through the adaptive P -value combination tests used by Bauer and Ko¨hne [3].
This approach allows information from earlier stages to be combined with that of later
stages, and treatment selection at adaptive interim analyses to be based on all previous
information from inside and outside the trial. Midtrial modifications are possible without
inflating the familywise type 1 error rate. The key ideas are: the construction of P -values
5with conditionally (sub)uniform distributions given the previous stages of the experiment, the
pooling of evidence across stages using prespecified combination rules, and the use of a closed
testing procedure to control the overall familywise error rate for the multiple hypotheses
under study. Section 1.2 discusses this first use of adaptive combination tests. The method
of adaptive combination tests is very general and Mu¨ler and Scha¨fer [29] show how it includes
group sequential tests, the two stage design of Thall, Simon, and Ellenberg [42], and further
generalizations as special cases.
Other formulations are possible. A Bayesian model-based design was proposed by Inoue,
Thall, and Berry [13] in which the decisions to stop early, continue Phase II, or proceed to
Phase III are based on predictive probabilities of concluding superiority of the new treatment.
The design uses survival time as a primary event as well as a short term event that is related
to the primary event by means of a mixture model. This model asks for the impact of the
short term event on the primary outcome to be demonstrated by the accruing information in
the trial. In this and other Bayesian formulations, parameters must be tuned and frequentist
properties must be shown by simulation to enforce the needed type I and type II error rates.
We now discuss three of the most important adaptive seamless designs. They are the
starting point for our proposal in Section 2, however, only the main ideas of the next section
are necessary for continuity.
1.2 Particular Designs of Interest
Bauer and Ko¨hne Design
The original Bauer and Ko¨hne Design [3] was largely in terms of a two stage experiment
for testing individual stagewise null hypotheses. However, it introduced a general structure
in which there can be multiple stages and test statistics on several hypotheses (perhaps
adaptively chosen) are available at each stage. This original version also introduced early
stopping boundaries and conditional error functions for this class of designs.
6Consider a global null hypothesis that is the intersection, H{1,2} = H1
⋂
H2, of hypotheses
from the first and second stages, respectively. If, for instance, changes in the endpoints or
the type of design are allowed, then the individual component null hypotheses may refer to
different potential endpoints or to different comparisons performed in the experiment, with
H2 selected or modified based on the first stage data. Based on the interim analysis of the
first stage data, it is decided whether to continue to the second stage or to stop the study
early for evidence of futility or efficacy. Let p1 and p2 be the observed P -values from each
stage from tests against their respective null hypotheses. Bauer and Ko¨hne’s procedure is
as follows:
1. Set a test for stage 1, determine the stopping rules for the interim decision, and pre-
specify the combination function, C, of p1 and p2 for the final analysis. A combination
function C(p1, p2) is a function of two (sub)uniform P -values that pools both pieces of
evidence into a (sub)uniform combined P -value. Bauer and Ko¨hne recommend the use
of Fisher’s inverse Chi square method; in this case pF = 1− F (−2 log(p1p2)), where F
is the cdf of the χ24 distribution.
2. Conduct stage 1 of the study and record p1.
3. Based on p1, decide whether to stop at interim (either rejecting or retaining H{1,2} and
H1) or to continue the study.
4. If the study is continued, use all information, internal and external to the study, to
design the second stage and its sample size.
5. Conduct stage 2 of the study, resulting in p2. The random variable P2 is constructed
to be independent of P1, given the first stage data, under H{1,2}.
6. Combine p1 and p2 using C(p1, p2) and decide for or against H{1,2} by comparing C
with an appropriate critical value. In case of rejection, decide for or against H2 using
p2.
7The design controls the familywise error rate strongly by applying the closed testing prin-
ciple. (The closed testing principle is a method of achieving strong control of the familywise
error rate with respect to a given set of hypotheses by considering and testing all possible
intersection hypotheses. The definitions of strong familywise error rate control and closed
testing procedures are given in Chapter 3.) The critical regions for tests at level α of the
individual null hypotheses, H1 and H2, are {p1 ≤ α} and {p2 ≤ α}.
The possibility of early stopping can be built into the experiment. Fisher’s criterion
leads to rejection of H{1,2} if p1p2 ≤ cα, where cα = exp{−12χ24,α}, and χ24,α is the (1− α)-th
percentile of the Chi-squared distribution with 4 degrees of freedom. Since p2 ≤ 1, one could
stop the experiment at the first interim analysis with rejection of H{1,2}, if p1 ≤ cα. Early
stopping for either futility or efficacy can also be allowed. One can choose α1, cα ≤ α1 ≤ α,
and modify the experiment to stop with rejection of H{1,2} when p1 ≤ α1. One can choose
α0, α ≤ α0 ≤ 1, with the requirement that the experiment stops without rejection of H{1,2}
when p1 ≥ α0. The overall type 1 error rate of the procedure can be directly calculated as
α1 + cα{logα0 − logα1}. This allows α0 and α1 to be set for a desired performance.
We give two brief examples of this method. The basic pieces are the (combination) tests
of individual hypotheses and the closed testing procedure which ensures strong control of
the familywise error rate.
Assume there are two treatments to be tested for superiority to a control, so that their
associated null hypotheses are HT1 and HT2 . Denote the intersection hypothesis as H{T1,T2}.
At interim, we decide which one to carry forward into the second stage. The final analysis
of the selected treatment includes the patients of both stages according to the prespeci-
fied combination rule. Assume that Treatment 1 is selected at interim to continue to the
second stage so that there is no second stage data available from Treatment 2. Conse-
quently, the intersection hypothesis H{T1T2} within this second stage is equal to HT1 and
its test is performed using only the test of HT1 . Since we have to reject both HT1 and
H{T1,T2} to declare treatment 1 significantly different from the control, we require that
8C(p1,T1 , p2,T1) < c and that C(p1,{T1,T2}, p2,T1) < c. This may expressed equivalently as
p2,T1 < min(A(p1,T1), A(p1,{T1,T2})), for suitably chosen A(p1,T1) and A(p1,{T1,T2}). These val-
ues may be thought of as conditional error functions (CEF’s), expressing the probability of
a type 1 error, given the first stage results.
As a second example, consider a study which was originally planned to investigate a
formulation of a new medicine, Treatment 1. Let HT1 be the associated one sided null
hypothesis. Assume that, at interim, safety problems are detected and it is decided to
discontinue the present treatment arm and continue with a different formulation. Let this
treatment, Treatment 2, be a prespecified modification of the original treatment. Let HT2 be
the associated new null hypotheses. At stage 1 no data are available for Treatment 2 and, vice
versa, at stage 2 no data is available for Treatment 1. The related stagewise P -values for the
intersection hypothesis are just the corresponding P -values from the elementary hypotheses
HT1 and HT2 . Applying the closed test procedure, HT2 is rejected if C(p1,T1 , p2,T2) < c and
C(p2,T2) < c. The first statement corresponds to rejection of H{T1,T2}; the second corresponds
to rejection of H2 and may be written more simply as p2,T2 < α. In some situations, the
first condition may not be severe and rejection of HT2 often just depends on the comparison
of p2,T2 with α. According to [8], the common practice of stopping a study for futility at
interim and starting a seemingly independent second study of Treatment 2 at level α can
often be justified from this point of view. However, this approach strains the credibility of
any final conclusion both because of the unplanned nature of the adaptation and because
the overall familywise error rate control is not explicitly demonstrated.
The theory of this design was not completely worked out in the original paper. Coun-
terexamples, where the design fails due to bad behavior of the P -values under certain classes
of adaptations are given by Liu, Proschan, and Pledger [26]. For a similar reason, more
justification of the use of closed testing procedures may be needed when the second stage
hypothesis is chosen data dependently from uncountably many candidates. Still, this is some
of the most important early work on adaptive seamless methods.
9Thall, Simon, and Ellenberg (TSE) Design
The Thall, Simon and Ellenberg (TSE) Design [42] is a two stage selection and testing design
that specializes the general structure of adaptive tests introduced by Bauer and Ko¨hne. The
type of adaptation allowed here is limited to selection of the best treatment in the first stage
so that it can be studied further in the second stage. This allows clarification of the role of the
alternative hypothesis, a definition of the power of the design, and the use of an optimality
condition for sample size determination. The relationship of this design to the more general
structure of adaptive designs will be explained toward the end of this subsection.
The specific goal is to identify the best of J experimental treatments, T1, . . . , TJ , and
to compare it to a control, T0. The observed data are binomial counts of success/failure
outcomes from patients on each treatment. The success probabilities for patients on the
different treatments are denoted by µTj , j = 0, 1, . . . , J . The null hypothesis under test
is H0 : µT0 = µT1 = . . . = µTJ and it is assumed that µT1 ≤ ... ≤ µTJ . The specific
parameters of the design are n1 and n2, the sample sizes of each treatment arm in the first
and second stages, respectively, and y1 and y2, the first and second stage cutoff values. They
are optimized to minimize a version of the total expected sample size, as explained below.
Let a(p) = sin−1
√
p, the variance stabilizing transformation appropriate for binomial
data. At stage i, for i = 1 or 2, let ni be the number of patients in each treatment arm, let






n = n1 + n2, pi = n1/n, and yi be the cutoff value to reject H0 at stage i. Given specific
values of these parameters, the procedure has two steps:
1. Randomize (J+1)n1 patients equally to T0, T1, . . . , TJ . Based on their results, compute
the first stage test statistic Y1 =
1√
2
max1≤j≤J(X¯∗1,Tj − X¯∗1,T0). If Y1 > y1 then select
treatment Ts having the highest observed success rate. Otherwise stop and accept H0.
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1− pi(X¯∗2,Ts − X¯∗2,T0)}. If Y2 > y2 then reject H0 and conclude µTs > µT0 .
Otherwise accept H0.
This design introduces concepts of size and power that are appropriate for its setting.
Call experimental treatment Ts “chosen” if it is selected in the first stage and then H0 is
rejected with the conclusion µTs > µT0 after the second stage. The size of the procedure
is defined as the probability that any Ts is chosen when H0 holds. The definition of power
is based on the recognition that no procedure can adequately discern between two group
means that are arbitrarily close and that only certain differences are medically important.
Let 0 < δ1 < δ2 be two constants such that success rate µT0 +δ1 is not considered a medically
important improvement while µT0 + δ2 is worthwhile. Let any Tj for which µTj ≥ µT0 + δ2
be considered an acceptable selection. For the purpose of defining power assume that at
least one Tj is acceptable and that no µTj lies in the interval (µT0 + δ1, µT0 + δ2). (This is
necessary because no test can discriminate between sufficiently close parameter vectors with
prespecified power.) The power function is then defined as 1− β(~µ) equal to the probability
that an acceptable choice is made given ~µ = (µT0 , . . . , µTJ ).
Design parameters must be set based on the desired size and power of the test. Since
power is a function of the alternative parameter configuration, it is necessary to decide which
alternative configuration is of interest. This is taken to be the least favorable configuration,
which minimizes power for given µT0 , δ1 and δ2. To this end the authors prove as their
“Theorem 1” the intuitive result that 1 − β(~µ) is minimized for given µT0 , δ1, and δ2 when
µT1 = · · · = µTJ−1 = µ0 + δ1 and µTJ = µT0 + δ2. Formulas for the size and power in terms of
design parameters n1, n2, y1, and y2 are derived by direct computation of the probability of
rejection under null hypothesis H0 and under the alternative least favorable configuration.
The expression for the size shows that it is independent of µT0 in the asymptotic limit. This
is as one would expect considering that each X¯∗i,Tj would tend to a normal distribution
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as sample size went to infinity and that the variances have been stabilized with respect to
shifts in µT0 .
Using these formulas, the design parameters may be chosen to minimize the risk adjusted
expected (total) sample size, 1
2
E(N |H0)+ 12E(N |~µ least favorable), so that the design will perform
reasonably well under both the null and the least favorable configurations. This criterion is
a form of Bayes’ risk and is also used by Liu and Pledger [25]. The specific minimization
procedure is not very interesting in itself, but it is a starting point for the routines that are
used to set design parameters in more complex situations.
A new feature that arises here is the possibility of a wrong selection. Although this is
not a type 2 error, since H0 is correctly rejected, it is still highly undesirable. Such an incor-
rect selection might have been considered a familywise type 1 error because it corresponds
to rejection of some true null hypothesis of no medically significant treatment effect at a
particular dose; it could be dealt with by imposing strong FWER control on the set of tests
of each H0 : µTj = δ1 , for j = 1, . . . ,J . Here, the effect is only identified as a third form of
error and its probability is denoted by γ. The authors show in a numerical study that this
error probability is small over reasonable parameter configurations.
This design may be shown to follow the general structure using combination tests orga-
nized into a closed testing procedure. The adaptation rule is rigid (entirely prespecified). In




to prespecified weights, to form a test of the selected treatment. Tests of the other required
(intersection) hypotheses may be written similarly, and the possibility of early stopping can
be included in the conditional error functions of these tests. As is sometimes the case with
rigid designs, the final test statistic here looks similar to the (sufficient) statistic we would
report in a nonadaptive treatment comparison experiment.
The contribution of the TSE Design is to specialize the adaptive structure to the two stage
hypothesis selection and testing situation with binomial data. This specialization permits
a meaningful discussion of the power of the design and allows concepts such as the least
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favorable configuration and the risk adjusted expected sample size to be introduced. For
its use, it is more convenient and slightly more efficient than the original Bauer and Ko¨hne
experiment. The restrictions to binomial data and two analysis points, as well as the desire
to incorporate covariate information in the analysis are all motivations for further work.
These needs are met in the next design.
Stallard and Todd Design
The Stallard and Todd Design, presented in [38], is a generalization of the TSE Design.
The goal is again to select the best of several experimental treatments and to confirm its
efficacy against a control. It extends the previous work in two ways: It uses the score
based method that can handle general forms of data, incorporate covariate information,
and allow for nuisance parameters. The design also lets the trial have a prespecified larger
number of stages, I ≥ 2, although selection must still happen at the first interim analysis.
The definitions of size and power developed in the TSE Design are applied and the least
favorable configuration is again used to set the sample size. However, there is more work in
calculating the distributions of the test statistics and in deciding on the stopping boundaries
of each stage than there was before.
The plan is a group sequential trial with up to I analysis points. It begins with J
experimental treatments, Tj, j = 1, . . . , J , and a control, T0. At the first interim analysis,
the best treatment is identified for further study based on the primary outcome. If this
treatment is sufficiently promising, then, in up to I − 1 additional stages, new patients are
recruited to this arm and to the control. Cumulative score statistics for the superiority of the
chosen treatment over the control are compared with upper and lower stopping boundaries.
A prespecified (familywise) type 1 error rate, α, and power to identify the correct dose under
a specified alternative are achieved. We now go over the details of this plan.
Let θTj be a measure of the superiority of Tj over T0, and let the null hypothesis be
H0 : θT1 = . . . = θTJ = 0. For j = 1, . . . , J , let Z1,Tj and V1,Tj be the efficient score and
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observed Fisher’s information for θTj at the first interim analysis. The selected treatment
is denoted by Ts, so that S is a discrete random variable with values in {1, . . . , J}. It is
assumed that all V1,Tj may be taken to be equal and that Ts is selected because it has the
largest observed Z1,Tj . At later analyses, specified by i = 2, . . . , I, let Zi,Ts and Vi,Ts denote
the efficient score and observed information for θs. The design enforces weak control of
the FWER, however it is possible to show that strong control is achieved as well. The
requirement enforced is that, under H0, the probability of concluding that any θTj exceeds
0 be at most α. The power of the study is defined as it was in TSE Design. Quantities
0 < δ1 < δ2 are identified such that δ1 is a marginal improvement of Ti over the control
and δ2 is a clinically meaningful improvement. Assuming that θT1 ≥ δ2 and that no θTj ,
j = 2, . . . , J , is in (δ1, δ2), the authors follow Thall, Simon, and Ellenberg [42], and argue
that the power is at least 1 − β, for all θT2 , . . . , θTJ not in (δ1, δ2), if it equals 1 − β in the
least favorable configuration. This is given by θT1 = δ2 and θT2 = . . . = θTJ = δ1. Power is
evaluated under this alternative.
The stopping decision at the ith analysis point is based on the value of the efficient score
statistic, Zi,Ts . For i = 1, . . . , I − 1, the test continues to the (i+ 1)th interim analysis if the
ith interim analysis takes place and Zi,Ts ∈ (li, ui). Two different spending functions are used
to give the upper and lower boundaries. The upper boundary points, {ui : i = 1, . . . ,I}, are
defined using α∗u : [0, 1] → [0, α], a non-decreasing function with α∗u(0) = 0 and α∗u(1) = α.
They must satisfy Pr(Zi,TS ≥ ui,Z1,TS ∈ (l1, u1), . . . ,Zi−1,TS ∈ (li−1, ui−1)|H0) = α∗u(ti) −
α∗u(ti−1), where ti is the proportion of the maximum information, Vmax, that will be available
at the ith interim analysis. Similarly, the lower boundary points {li, : i = 1, . . . ,I} are
defined using a nondecreasing function, α∗l : [0, 1] → [0, 1− α], with α∗l (0) = 0 and α∗l (1) =
1 − α. The corresponding condition is that Pr(Zi,TS ≤ li,Z1,TS ∈ (l1, u1), . . . ,Zi−1,TS ∈
(li−1, ui−1)|H0) = α∗l (ti)−α∗l (ti−1). This method ensures that the upper and lower boundaries
meet at the last analysis, however, it is necessary to search over Vmax to ensure the desired
power at the least favorable configuration.
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To implement the design using given error spending functions, forms for the test statistics
and specific distributional results are needed. Forms for θ and the corresponding efficient
score and observed information in many settings are given by Whitehead [45]. Under a
local alternative and appropriate regularity conditions, it is possible to use the following
approximation in a study comparing a single experimental treatment to a control: Z1 approx∼
N(θV1,V1) and Zi − Zi−1 approx∼ N(θ(Vi − Vi−1),Vi − Vi−1), with Zi − Zi−1 independent of
Zi−1, for i = 1, ..., I. The generalization to a multivariate normal (approximate) distribution
of a vector of score statistics is discussed in Section 4.2.
These results enable the first stage cutoff values to be approximated from the distribution
of the maximum of correlated (multivariate) normal random variables. Subsequent cutoff
values are then derived by considering the distribution of the score statistic at a later analysis
point as the sum of two pieces: (1) the first stage statistic; and (2) an independent increment,
normally distributed with known mean and variance. Numerical calculation of integrals is
then used to set the boundaries.
Overall, this design is successful in accommodating other forms of data, allowing covari-
ates and/or nuisance parameters, and making decisions based on the amount of information
gathered rather than the treatment of a preset number of patients. The extension to I ≥ 2
analyses is useful too. A weakness of the original paper is that the asymptotics were not
correctly worked out. However, the needed properties can be found directly from the un-
conditional distribution of the score statistic under a local alternative, and the design is still
valid. It is clearly useful in applications.
This design motivates work in several directions. One is the use of multiple endpoints as
Stallard and Todd did in [39]. Another is to consider the data dependent promotion of more
than one dose into the second stage, and/or the the addition of new treatments. The next
section makes such a proposal and identifies an important application.
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Chapter 2
A New Two Stage Limb-Leaf
Procedure
2.1 Potential Benefits of Dose Addition
Given any unknown dose response curve, there is an important distinction between d∗, a
dose with the desired effect (or the maximum possible effect), and dˆ∗, its estimated value.
The corresponding effects of these doses, θd∗ and θdˆ∗ , could be different in a meaningful way,
with θdˆ∗ < θd∗ . Heuristically, the more closely dˆ
∗ approximates d∗, the greater the chance
that the study will reject the global null hypothesis, H0 : θd = 0 for all doses d, and the
closer the final dose recommended to patients will be to that which gives them the desired (or
maximum) benefit. This is a strong motivation for a better exploration of the dose response
curve in adaptive seamless designs.
One possibility for better exploration in an existing design such as the TSE Design [42]
(described in Section 1.2) is to start a study with a large number of closely spaced first
stage doses. However, there are reasons to expect the performance to suffer. Under the
alternative, the true d∗ may be hard to identify because it will have many competitors, some
with nonzero effects. Also, a large number of first stage patients will have to be randomized
to areas of the dose response curve that are not relevant to the final recommendation. Under
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the global null hypothesis of no treatment effect at any dose, many patients will have been
treated before an early stopping decision can be made. We note that under either hypothesis,
treating an excessive number of patients with an ineffective treatment or with ineffective
doses of an otherwise worthwhile treatment is not ethically desirable. Some of these issues
are acknowledged by Thall, Simon and Ellenberg in the final sections of [42], however they
play less of a role in the case where there are only a few first stage doses with broad spacing
between them.
We propose to use a two-stage selection procedure in which second stage doses are not
only promoted from a modest number of first stage candidates but in which new doses may
also be added in response to first stage results. We aim to improve the estimation of d∗ and
to use patients’ data more efficiently, this being particularly so under the global null, where
the probability of early stopping should be large. Such promotion and addition decisions
could be based on all the available information, including efficacy and toxicity, whether this
information comes from within the study or from an outside source.
Two approaches will be developed. One is a completely free addition of second stage
doses out of (a countable collection of) all possible dose levels. This first approach will be
developed as an extension of known methods in Chapter 3. It is then criticized in Chapter 4
because of its risk of low efficiency and because it does not recognize the inherent structure
of the two stage selection process. A more systematic “limb-leaf” approach is developed in
Chapters 6-8 as the favored solution. This solution is built from a “horizontal” test that is
fundamentally different from the P -value combination rules that have been used in adaptive
designs, and whose performance is tailored to the needs of a limb-leaf exploration process.
It would also be valid to implement a limb-leaf strategy using the more generic method of
Chapter 3; we do not oppose this given the result in Chapter 5 that there does not exist a
uniformly best multiple testing procedure in this setting.
The Limb-Leaf Design organizes a prespecified set of candidate doses into two nested
partitions. The first uses a coarse increment, and we call it the full set of “limbs”, Lfull =
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{Lj : j = 1, . . . , |Lfull|}. We intend for there to be only a few limbs, and reasonable values
for |Lfull| are 1 to 4. We can also consider the control dose to be L0.
The second partition is finer. To any limb Lj we may associate the “leaf” doses `j =
{ljk : k = 1, . . . ,Mj}. The full set of leaves, `full, is then `1 ∪ · · · ∪ `|Lfull| and the second
partition is S = Lfull ∪ `full. We call S a limb-leaf system because it includes the limbs as
well as their leaves.
In referring to a set of limbs, we may write them as {Lj : j = 1, . . . , J}. In referring to
a set of leaves (not necessarily all associated with the same limb) we may sometimes relabel
them as {lk : k = 1, . . . , K} for convenience.
In the two stage selection process, the first stage investigates only the limb doses. At
the end of this stage, there is an interim analysis in which it is decided which limbs deserve
further study in the second stage as well as which of their leaves. These leaves are intended
for further exploration around an area of promising activity, in order to better approximate
d∗. The promotion/addition decision can be based on all available information, such as
efficacy, safety, and cost, from sources internal or external to the study. In the most general
case the number and locations of the promoted limbs and the number and location of the
added leaves can all be adaptively chosen. Later, we will specialize to only select one limb
and a variable number of leaves to promote.
At the second analysis, a dose is selected for final confirmation. The remainder of the
study may use a group sequential design to confirm the efficacy of this dˆ∗ (the best available
approximation to d∗). The study is adaptively seamless in the sense that all of the stages
will be allowed to contribute to the final determination of efficacy.
In order to set the parameters of dose addition designs and to justify these schemes
in comparison with existing adaptive seamless designs, we use the risk adjusted expected
sample size, w1E(N |Hglobal null)+ w2E(N |Hchosen alternative), with w1 +w2 = 1. In the
comparison between a Limb-Leaf Design and a standard seamless design in Chapter 8, we
identify and choose a “least favorable locatable” alternative. Here w1 and w2 are weights
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expressing the prior belief in the efficacy of the drug. In applications such as ALS research
in Section 2.2, it may be realistic to choose w1 to be as high as .9 (with w2 as .1). Generally,
if it is too difficult to find a least favorable configuration in closed form, one might set
parameters to guarantee desired performance under a chosen alternative, which could be a
least favorable configuration among a more restricted class of dose response curves. One
would then use simulation studies to assess the performance of the dose addition design
against its competitors under plausible alternatives.
We note that limb-leaf designs imply a different, stronger role for the clinicians in the
design and interim analyses of the study. They will provide expert judgement on the range of
doses to consider, the classification of these doses into limbs and leaves, and the parameters
of the search pattern (Section 7.1). This will be done in consultation with the statistician.
Potential sources for prior knowledge include preclinical toxicity studies, human or animal
trials, pharmacodynamic models, the behavior of related therapies in the same illness, and
the behavior of the given treatment in related illnesses. We anticipate that clinicians will
appreciate this greater chance to apply their knowledge to influence the design of the study.
2.2 Identification of ALS Research as a Potential Ap-
plication
Amyotrophic Lateral Sclerosis is a devastating, incurable, neurodegenerative disease with an
annual incidence rate of 1 to 2 per 100,000 person years. It usually leads to death within
2-4 years of onset. The disease mechanism is not fully understood, but it is thought that
oxidative stress and mitochondrial impairment contribute to neuronal loss.
The Food and Drug Administration (FDA) has approved only one drug for the disease:
Riluzole (Rilutek). Clinical trials with ALS patients showed that Riluzole lengthens survival
by several months, and may have a greater survival benefit for those with a bulbar onset
of the disease. The safety and tolerability of this medication is an issue and those taking
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the drug must be monitored for liver damage (occurring in 10% of patients) and other side
effects. There is hope that the progression of ALS may one day be slowed or stopped by
new medications or a combination of drugs.
In the design of studies to investigate new ALS treatments, it is important to note that
the treatment effect of any new medication is likely to be small and patient benefit may exist
over only a limited dose range. There may be no justification for assuming a monotone dose-
response relationship; the mechanism by which a new drug or combination therapy works
may be complex, and benefits may decline before an actual toxicity occurs. There may be
several simultaneous mechanisms of action, with negative interactions between them. For
instance, Riluzole is believed to reduce damage to motor neurons by decreasing the release
of glutamate via activation of glutamate transporters. In addition, the drug may offer other
neuroprotective effects by means of sodium and calcium channel blockades, as reported by
Hubert et al. [12]; inhibition of protein kinase C, as reported by Noh et al. [30]; and
the promotion of NMDA receptor antagonism, as reported by Beal, Lang, and Ludolph [4].
An incorrect assumption of a monotone dose response relationship is a favored explanation
for the failure of a recent major ALS study, as argued by Ludolph and Jesse [27]. We
conclude that to extract small treatment benefits in ALS, it may be necessary to explore a
dose response curve carefully and even to approach a toxicity boundary (without actually
crossing it).
Existing Phase II and Phase II/III designs for ALS research are reviewed by Schoenfeld
and Cudkowicz [36]. These include: futility designs, lead in designs, multidrug ranking
designs, and sequential designs such as the “Christmas Tree”. A classic example of the
futility design referenced there is a Phase II trial of Coenzyme Q10 by Levy et al. [24],
which found insufficient evidence to justify a further confirmatory study. (See also Levin
[22].) According to the review, there is a large pipeline of potentially beneficial treatments
and an extended debate about methods to test new drugs. The recommendation is that
many different designs be developed and that a symposium on clinical trial design become
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a regular part of meetings of the ALS research community.
The proposed Limb-Leaf Design combines and enhances many of the known approaches.
The possibility for early stopping after initial (first stage) investigation is similar to the
concept of a futility design, the advantages of multidrug (or multidose) ranking are also
gained, and group sequential continuation after the selection stages could also be allowed.
The addition of doses at adaptively determined locations and a systematic process of dose-
response exploration are potentially valuable enhancements.
A controversy exists regarding the appropriate choice of endpoint(s) for Phase II or Phase
II/III trials. Survival is the outcome of primary interest and should be chosen for Phase III
studies. However, for Phase II studies, there is a legitimate case that a measure of muscular
function such as the ALSFRS-r could be used. Such a measure is more quickly observed
and may be closer along the causal chain to the actual disease process. The ALSFRS-r was
used as the primary outcome by Levy et al. in [24], and further evidence for its applicability
was given by the same authors in [19]. However, as reported by Bensimon, Lacomblez, and
Meininger [6], a major trial of Riluzole showed a survival benefit without a corresponding
benefit on the rating scale. (See also Levin et al. [23].) Clearly, this controversy needs to be
resolved by experts within the field. In order to recognize the potential need to accommodate
multiple endpoints, we will suggest how this could be done for Limb-Leaf Designs in Chapter
9.
We believe that Limb-Leaf Designs could offer worthwhile advantages for the study of new
ALS treatments. An adaptive seamless design is desirable because of the scarcity of patients
available to be enrolled in such a study, the organizational efficiency of an integrated program,
and the urgent need to bring out any successful therapy to those currently suffering from the
disease at the earliest time. Given previous experience, it might be reasonable to expect such
a trial to have to reveal a small dose range over which there would be a worthwhile treatment
effect. Also, within such a dose range, one would need to locate a dose with the desired level
of effect (and/or the maximum effect) as well as possible, both to improve the trial’s chance
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of success and to enhance the treatment’s benefit to future patients. The opportunity to
end a study early after a crude investigation of the dose response curve with negative results
would also be highly desirable. These are features of the Limb-Leaf Design to be developed
in Chapters 6-8. Further advantages include the benefit to participating patients of having
a greater chance of being assigned to doses that are effective (as opposed to not), and the
opportunity for clinicians to contribute more of their knowledge and intuition to the process
of study design.
Before approaching our preferred formulation of the Limb-Leaf Design, we will discuss
an extension of the original work by Bauer and Ko¨hne.
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Chapter 3
Basic Dose Addition: Formulation
and Justification
The method of Bauer and Ko¨hne (see Section 1.2) can be generalized to allow data dependent
promotion and addition of doses as, for instance, in a Limb-Leaf Design. We begin with the
basic background on closed testing procedures and combination tests.
3.1 Closed Testing Procedures and Combination Tests
Suppose there are J null hypotheses, Hj : θj ≤ 0 for j = 1, . . . , J , available to be tested
in a given experiment. Inflation of the number of type 1 errors committed could result
from testing each hypothesis at its nominal α value. Instead, these tests must be organized
into a multiple testing procedure, and an appropriate generalization of the type 1 error rate
condition must be imposed. In an adaptive design, final test statistics may not be available
on all J hypotheses, but the approach given here still controls for the presence of these other
hypotheses and the biases introduced by selections.
A multiple testing procedure is a rule to decide which of the available hypotheses to reject.
Its familywise error rate (FWER), under a particular set of parameter values, (θ1, . . . , θJ), is
Pr( Reject any true Hj). Since the event {The selected true null hypothesis is rejected} ⊆
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{Any true hypothesis is rejected}, if the familywise error rate is controlled at level α for a
particular set (θ1, .., θJ), then, even if we select which hypotheses to test in a data dependent
way, the probability of committing a false rejection is less than or equal to α.
So far, this only concerns control of the familywise error rate under a particular pa-
rameter vector (θ1, . . . , θJ). There is a consensus in the literature that a multiple testing
procedure needs to control the familywise error rate strongly, which means that this error
rate needs to be at most α for all possible vectors (θ1, . . . , θJ). That is, Pr( Reject any true
Hj) ≤ α,∀ (θ1, . . . , θJ). Using such a procedure, the probability of choosing to focus on any
hypothesis and then falsely rejecting that hypothesis is at most α regardless of the parameter
configuration.
The argument for strong control of the familywise error rate as opposed to weak con-
trol (under only the null hypothesis) is made by Tamhane, Hochberg, and Dunnett in [41],
where procedures that do not control the FWER strongly are criticized. The authors’ ex-
ample considers the problem of finding the minimum effective dose, MED = min{j : θj =
effect of treatment j > 0}, in two separate experiments. The first uses J = 4 treatments
and the second uses J = 5. Assume that the true MED = 5 and that the familywise error
rate is controlled in each experiment (weakly) only under H0J : θ1 = . . . = θJ = 0. Then,
estimating dose 4 to be the MED would be a correctly controlled type 1 error in the first ex-
periment (where the global null hypothesis is true) and not in the second experiment (where
the global null hypothesis is false). Because the true MED can be any one of the dose levels,
control of the FWER is needed and only strong control is acceptable.
A general family of procedures that control the FWER strongly is the class of closed
testing procedures. A closed testing procedure for a given set of hypotheses {Hj : j =
1, . . . , J} is as follows. For each subset S of {1, . . . , J}, define the intersection hypothesis
HS =
⋂
j∈S Hj . Construct a level α test of each HS. Such a test, for instance, might
combine tests of the individual Hj’s using the Bonferroni correction or some other more
efficient adjustment for the multiplicity of hypotheses. Finally, the hypothesis Hj : θj ≤ 0
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is rejected overall iff HS is rejected for every set S such that j ∈ S. The proof that this
procedure controls the FWER strongly is as follows. Let S∗ be the set of the indices of
all true hypotheses. For a familywise error to be committed, HS∗ must be rejected. Since
HS∗ is true, Pr(Reject HS∗ ) ≤ α. Therefore, the probability of a familywise error can be
no greater than α. A further discussion on closed testing procedures, an argument for why
there is no need to look beyond this class, and their applications to Limb-Leaf Designs are
given in Chapter 5
In order to use a closed testing procedure in a multistage trial, we must consider how to
form the tests that constitute it. The established approach is to use combination tests that
pool stagewise summary measures of evidence.
Consider a null hypothesis of no treatment effect, H0, that is studied in I≥ 2 stages of an
experiment. Often, the evidence that emerges from the ith stage is expressed as a P -value,
Pi, interpreted as the evidence against H0 in stage i. Equivalently, a Z-value is reported
according to Zi = Φ
−1(1−Pi). It is commonly assumed that under H0, Pi ∼ U(0, 1) (or Zi ∼
N(0, 1)) and that stagewise P -values are independent. Rigorously, Pi must have a conditional
sub-uniform null distribution. It must satisfy supθ∈Θ0Pr(Pi ≤ u) ≤ u,∀u : 0 ≤ u ≤ 1
conditional on the data from previous stages of the exeriment.
Methods of testing H0 by combining Pi’s across stages come from meta-analysis. Two
preferred choices are Fisher’s inverse Chi-square, and the weighted inverse normal method.
The Inverse Chi-square method follows from −2 log(P1P2 · · ·PI) H0∼ χ22I . The associated
test rejects H0 at level α if the left hand side exceeds χ
2
2I,α. The associated P -value is the
value of α for which equality is achieved.
Another means of combining evidence is the weighted inverse normal method (Weighted
Rule). Here, a set of weights {w1, . . . , wI} is prespecified such that ΣIi=1w2i = 1. The level
α test rejects if ΣIi=1wiZi > zα, where zα is the (1− α)th percentile of the standard normal
distribution.
These combination rules can be used in sequence, and the type 1 error rate will be
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protected when stages of the study are designed adaptively as long as the proper structure is
observed. Consider the Weighted Rule, with weights w1 and w2, for a two-stage study. After
stage 1, it could be decided to design stage 2 as a combination of M(Z1) sub-stages, also
to be evaluated by the weighted inverse normal method. Before conducting these M(Z1)






2 must be specified. Let the
results of these substages be expressed by the Z-values Z21...Z2M(Z1). The combined test
statistic from the second stage would be Z2, where w2Z2 = w21Z21 + ... + w2M(Z1)Z2M(Z1)
and the overall test would still be based on Z = w1Z1 + w2Z2.
This technique can be used recursively in such a way that the wi’s can depend on previous
data and the number of stages can also depend on the emerging data. This leads to the
method of variance spending. We may consider that each chosen weight, wi, spends an
amount w2i of the variance, and the study ends when the total variance spent equals 1, the
variance of the final Z-statistic. However, if such a variance spending rule is not followed the
resulting procedure will not control the type 1 error rate correctly.
There are two other combination methods worth noting. Tippett’s rule assigns a P-value
to H0 based on min(P1, . . . , PI) and accepts or rejects accordingly: specifically, PT = 1 −
(1−min(P1, . . . , PI))I . This combination rule is recognized for good performance by Goutis,
Casella, and Wells [10]. It is used implicitly in several adaptive seamless designs, such as those
of TSE and Stallard and Todd, to combine evidence for a combination hypothesis within
a stage rather than across stages. When applied to Z-values, we will call it the Maximum
Rule because the smallest P -value corresponds to the largest Z-value. This Maximum Rule
is different from the “Maximum Rule for P -values”, according to which a level α test of H0
rejects if max(P1, . . . , PI)
I < α.
The review of the combination of evidence through the combination of P -values by Goutis,
Casella, and Wells [10] does not produce a clear winner and states that the choice of com-
bination rule for a particular setting is a matter of judgement. In flexible designs where
the adaptation rule is impossible to write explicitly, expressing the results by a combination
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of P -values may be the only feasible method. This is the dominant approach in adaptive
designs and it has been used very successfully.
3.2 A Useful Formulation
The following representation of a two stage study makes it easy to generalize the method
of Bauer and Ko¨hne. We use d to refer to any given dose, and θd to refer to its effect rel-
ative to control. For any collection of doses, D, let HD be the associated null hypothesis,
θd = 0 : ∀d ∈ D. Let Zi,D denote the Z-value against hypothesis HD in stage i. When D is
a singleton, we will suppress its identity as a set and write expressions such as HL1 and ZL1 .
Assuming that results on all doses are available in the first stage, a two stage study can be
represented as:
Hypothesis Stage 1 Stage 2 Combined Statistic
Statistic Statistic
HL1 Z1,L1 Z2,L1 ZL1 = CL1(Z1,L1 , Z2,L1)
HL2 Z1,L2 Z2,L2 ZL2 = CL2(Z1,L2 , Z2,L2)
...
HLJ Z1,LJ Z2,LJ ZLJ = CLJ (Z1,LJ , Z2,LJ )
H{L1,L2} Z1, {L1,L2} Z2, {L1,L2} Z{L1,L2} = C{L1,L2}(Z1, {L1,L2}, Z2, {L1,L2})
H{L1,L3} Z1, {L1,L3} Z2, {L1,L3} Z{L1,L3} = C{L1,L3}(Z1, {L1,L3}, Z2, {L1,L3})
...
H{1,...,J} Z1,{L1,...,LJ} Z2,{L1,...,LJ} Z{L1,...,LJ} = C{L1,...,LJ}{Z1,{L1,...,LJ}, Z2,{L1,...,LK}}
Here the Zi,D values are pooled across stages by prespecified combination rules. The com-
bined ZD values are then used to test individual effects through a closed testing procedure:
Reject any Hd iff HD is rejected according to ZD > zα, ∀D 3 d.
The set of first stage Z1,D values which are available is prespecified. The set of second
stage Z2,D values which are available is a function of the first stage data because, in general,
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treatments could be dropped from or added to the study.
One way to form Zi,D values for intersection hypotheses within each stage that have
the desired conditional sub-uniform property is by maximization and rescaling. This is a
special case of Tippett’s rule. Let the second stage test statistic for H{L1,L2} be Z2,{L1,L2} =
f{L1,L2}{Z2,L1 , Z2,L2}, with f{L1,L2} defined as follows. Under an adaptation such that only
one element of {Z2,L1 , Z2,L2} is present, f{L1,L2} returns that value; if both are present,
f{L1,L2} = Φ
−1(F ( max(Z2,L1 , Z2,L2))), where Φ is the standard normal cdf and F is the cdf
of the maximum of the two second stage Z-values under H{L1,L2}. The null distribution of
Z2,{L1,L2} is then uniform conditional on each adaptation. The function f{L1,L2} generalizes
in the obvious way to an fD for any other set of doses, D.
To accommodate doses whose first stage data are not available, or vice versa, doses
whose second stage data are not available is straightforward. Call a simple or intersection
hypothesis testable if a Z- value corresponding to it or to any of its sub-hypotheses exists
in the second stage. For instance, H{L1,L2} is testable iff Z2,L1 and/or Z2,L2 is available.
Define the combined Z-value for any set of hypotheses D not tested in the first stage as
its second stage Z value, Z2,D. For instance, if HL2 is not tested in the first stage, we set
ZL2 = CL2(Z1,L2 , Z2,L2) = Z2,L2 . We now use the restricted procedure: Reject Hd iff HD
is testable and HD is rejected (ZD > zα), ∀D 3 d. We note that, by the construction
above, if Hd is testable then so are HD, ∀D 3 d, and that the closed testing principle still
applies to protect the FWER.
A clearer way to view this procedure is as an extension of the conditional rejection
probability (CRP) principle of Mu¨ller and Scha¨fer [29]. Let the data observed up to the
adaptation point be expressed by the random vector X . Then, the CRP principle states
that the decision function ψ1 may be changed to any other decision function ψ2 for which
the inequality E(ψ2|X ) ≤ E(φ1|X ) holds true under the null hypothesis.
From this point of view, our design adapts a prespecified closed testing procedure by
using adaptations that preserve or reduce the conditional rejection probability of each test
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within it. Specifically, in the design that promotes all doses to the second stage, the test
statistic for an arbitrary hypothesis, HD, is ZD = CD(Z1,D, Z2,D), with rejection occurring
iff ZD > zα. Given the first stage data z1,D, the probability of rejection, Pr(CD(z1,D, Z2,D) >
zα), may be expressed in terms of the associated conditional error function as Pr(Z2,D >
AD(z1,S)). Given the first stage data and a possible adaptation, there are two cases for the




2,D  N(0, 1), in which case Pr(Za2,S >
AS(z1,S)) ≤ Pr(Z2,S > AS(z1,S)), or HD is declared untestable, in which case Pr(Za2,D >
AD(z1,D)) is defined as zero. In either case, the conditional rejection probability principle
guarantees the validity of the test and of the procedure as a whole. This argument will be
developed in Chapter 5.
Mu¨ller and Scha¨fer [29] acknowledge that designing good conditional error preserving
rules in the case of even a single hypothesis is not trivial. For a system of tests this could be
even more complicated, but a desirable approach would be to begin with a good and efficient
group sequential design that controls the FWER using the closed testing principle. Such a
design could be optimized for a certain probability to correctly identify an effective treatment
in a least favorable configuration, and to have a prespecified probability of stopping early
under the global null. Potential adaptations from a restricted class could be specified and
the performance under these adaptations could be verified. Two examples are given next.
The first uses data dependent promotion of first stage doses. The second also allows data
dependent dose addition.
Two Basic Examples
Forwarding More Than One Dose : Consider a two stage experiment with the prespecified
set of doses {Lj : j = 1, . . . , J}. Based on the first stage data, it is decided which, if any, of
the first stage doses to promote and study further. Following Brannath, Posch, and Bauer
[7], the second stage could be defined as a combination of substages, and so on, through
recursion. The second stage could be redesigned following first stage results to achieve a
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needed conditional power.
The base design could be optimized for power under a least favorable configuration under
the assumption that all doses are promoted. Assuming a first stage sample size of n1 per arm
and a second stage sample size of n2 per arm, an efficient combination rule for each hypothesis








Z2,D. Another possibility would be
to optimize under the assumption that only the dose with the greatest first stage performance
will be promoted. The resulting design can be made to be equivalent to the TSE Design,
except that it also allows the promotion of more than one first stage dose.
An example of the possible results from a trial that studies five doses across two stages
is given below.
Hypothesis Stage 1 Stage 2 Combined Statistic
(Dose #’s) Statistic Statistic
HL5 Z1,L5 ∅ ∅
HL4 Z1,L4 ∅ ∅
HL3 Z1,L3 Z2,L3 ZL3 = CL3(Z1,L3 , Z2,L3)
HL2 Z1,L2 Z2,L2 ZL2 = CL2(Z1,L2 , Z2,L2)
HL1 Z1,L1 ∅ ∅
∅ denotes a missing value and/or an untestable dose.
Intersection hypotheses are not shown.
It was adaptively decided to forward doses L2 and L3 for further study. Assuming that
HL2 and HL5 are true, and that HL1 , HL3 , and HL4 are false, committing a familywise error
requires the rejection of H{L2,L5}. In our formulation:
C{L2,L5}(Z1,{L2,L5}, Z2,{L2,L5}) = C{L2,L5}{f{L2,L5}(Z1,L2 , Z1,L5), f{L2,L5}(Z2,L2 , Z2,L5 )}
> zα.
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If, for instance, Z1,L3 and Z2,L3 are the maxima of their respective stages, the statistics
required to test HL3 have a convenient ordering. For the first stage statistics,
(Z1,L3) ≥ f{L2,L3}{Z1,L2 , Z1,L3} ≥ · · · ≥ f{L1,L2,L3,L4,L5}(Z1,L1 , . . . , Z1,L5)
and similarly for the second stage statistics,
(Z2,L3) ≥ f{L2,L3}{Z2,L2 , Z2,L3} ≥ · · · ≥ f{L1,L2,L3,L4,L5}(Z2,L1 , . . . , Z2,L5),
so that rejection of HL3 occurs if and only if
C{L1,L2,L3,L4,L5}{f{L1,L2,L3,L4,L5}(Z1,L1 , . . . , Z1,L5), f{L1,L2,L3,L4,L5}(Z2,L1 , . . . , Z2,L5)}
> zα.
This means that of all the 16 tests involving dose L3, it is necessary and sufficient to only
consider one.
It is assumed that the combination functions are the same for each hypothesis and, as in
the case for the four combination rules stated previously, this function is nondecreasing in
both of its arguments.
If doses other than the maximum are tested, the same criterion can be applied to any
selected dose. This would be a conservative procedure. A small gain in power might be
possible by individually considering each of the intersection tests required to reject a simple
hypothesis. This is because the relevant combined ZD values may be higher (more extreme)
than the conservative lower bound. Still, not all of the test would need to be done.
Basic Dose Addition: Adaptive dose addition can also be accommodated. Let the first
stage doses be {Lj : j = 1, . . . , J} and let a large collection of possible (new) second stage
doses be {lk : k = 1, . . . , K}. For convenience we assume that one first stage dose (Ls) is
selected for promotion and that a collection of second stage doses {lk : k ∈ S} is added
adaptively.
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In the evaluation of the closed testing procedure following the experiment, those members
of {lk : k = 1, . . . , K} that are not tested in the second stage may be totally ignored. Consider
the test of any composite HC , C = F ∪ G ∪H, where F is a collection of first stage doses,
G is a collection of second stage doses studied in the experiment, and H is the set of those
second stage doses not actually used in the second stage. For convenience, we relabel the
elements of G as l1, . . . , l|G|. The second stage test statistic for HC will be
Z2,C = f{F∪G∪H}(Z2,Ls , Z2,l1 , . . . , Z2,l|G|).
This test, in the first and second stages, is then redundant with that of HC′ = F ∪ G
and may be ignored; among the infinite number of potential second stage doses, only those
actually studied have an influence on the final analysis.
The ordering properties discussed above continue to hold and they allow reductions in
the collection of tests that is sufficient for conclusions on any dose of interest. For instance,
if L1 has the largest observed Z-value in the first stage,
Z1,L1 ≥ f{L1,L2}(Z1,L1 , Z1,L2) ≥ f{L1,L2,L3}(Z1,L1 , Z1,L2 , Z1,L3) ≥ . . .
and if it again has the largest observed Z-value in the second stage, then only one test is
necessary and sufficient to confirm its efficacy. If it ranks kth largest in the second stage,
then k tests are necessary and sufficient to consider.
The tests of leaf doses offer more complications. Even if l∗ has the greatest observed effect
among the second stage doses, it is still necessary to consider J tests in order to confirm the
effect at l∗. These are the tests of the hypotheses corresponding to the sets of doses:
{L∗1, l1, . . . , lK},
{L∗1, L∗2, l1, . . . , lK},
...




2, . . . , L
∗
J denote the J doses under study in the first stage ranked in increasing
order by their observed effect sizes. The first stage results on doses such as L∗1 could be very
poor, and the failure to reject any of these hypotheses leads to a failure to reject overall.
This is problematic, especially in the context of a Limb-Leaf Design where poor performance
on some first stage limbs is to be expected. In the next section we give further attention to
this issue and make a proposal for improvement.
Adaptive addition of doses is mentioned in the appendix of a paper by Bauer and Keiser
[2]. Their development is similar, but we would like to claim that the presentation here (in-
dependently derived) is more elegant. The problem of forwarding an adaptively determined
number of doses was discussed by Kelly, Stallard, and Todd [20] and by Stallard and Friede
[37]. The first version achieved only weak control of the FWER. The second attempt has
strong control only if the number of doses to be forwarded is prespecified, and otherwise it
needs extensive simulations. The method given here does not have these drawbacks.
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Chapter 4
Criticism of the Existing Tests and a
Proposal for a New “Horizontal” Test
4.1 Shortcomings of the Basic Dose Addition Method
The clear danger in the basic version of dose addition is the tendency to fail to confirm the
effects of added doses because of poor first stage performance at other, irrelevant dose levels.
For instance, consider a two stage study with one original dose, L1, and one leaf dose to









Z2,D, is prespecified to test the global null hypothesis. This is a reasonable choice
for a combination rule because it would lead to efficiency in the case that L1 were promoted
and no addition occurred. In the case of normally distributed data with known variance, the
resulting test depends on the (sufficient) overall mean and coincides with the UMP test.
However, if first stage results on L1 are poor (or worse, strongly negative), and the









Z2,l1 . In spite of a large value of Z2,l1 (strong
evidence for efficacy at l1), the overall test statistic could be greatly reduced by a low or even
negative Z1,L1 . Failure to reject the global null then leads to failure to confirm the efficacy
of l1.
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We stress that, because overall rejection of a hypothesis by a closed testing procedure
requires rejection in the test of every composite hypothesis containing it, the tendency of
any such test to fail due to poor first stage results on other dose levels (far from the most
effective dose) limits the performance of the procedure as a whole. In a Limb-Leaf Design, it
is assumed that treatment effects will be low, or even negative, relative to the active control,
over large parts of the studied dose range. Therefore, we require any method of combining
data across stages to be robust to poor first stage results at these dose levels.
It is possible to consider this problem at the level of combination functions (or equiv-
alently, conditional error functions). A robust choice of combination rule is the Maximum
Rule, CMax(Z1,D, Z2,D) = Φ
−1[max{1 − Φ(Z1,D), 1 − Φ(Z2,D)} 12 ] , where Φ is the standard
normal CDF. As commented in 3.1, this is Tippett’s rule, expressed in terms of stagewise
Z-values.
Unfortunately, in the case that L1 performed well and was promoted instead of replaced,
there would be problems with efficiency and credibility. One full stage of data would be ef-
fectively ignored by this rule; this is inefficient and contrary to the principles of an adaptive
seamless approach. Options between these two extremes– maximizing efficiency in the case of
promotion and maximizing robustness in the case of a switch– are possible by modifications
of the combination function (conditional error function). However, these rules lack a justifi-
cation in terms of the fundamentals of the problem, involve data distortion, and can strain
credibility. One would like to do better. Given that for bivariate normal data, with a single
unknown parameter, µ ∈ R2, there is no uniformly most powerful test of H0 : µ = (0, 0)T
versus H1 : µ ∈ R+ ⊗ R+, we cannot expect a uniformly most powerful test in our situa-
tion. What we can seek is an adaptive test that is well motivated, interpretable, and has a
favorable tradeoff between efficiency and robustness.
In the following section we propose a “Horizontal Rule” with a fundamentally different
structure that cannot be expressed as a combination rule for P -values. This rule is well
suited to the needs of the Limb-Leaf Design. As shown in Section 4.3, in the case of good
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first stage performance, the efficiency rivals that of the Weighted Rule, and in the case of
poor first stage results, the the robustness is equal to that of the Maximum Rule. There is
also a small additional contribution to the power of the test from its new structure. The
Limb-Leaf Design using the Horizontal Rule is developed in Chapter 6.
4.2 Proposal for a “Horizontal” Test
The Horizontal Test respects the identities of individual doses. By keeping data from doses








Z2,l2 do not arise.
The previous trade-off between robustness and performance is modified and some of the
distortions of reducing stagewise data to P -values are avoided. The Horizontal Test is
compatible with the full score-based method for handling multiple forms of data. We present
it in a simple case.
Consider outcomes that are normally distributed with common known variance σ2. Let
the first stage of a two stage experiment use the set of limb doses Lfull = {Lj : j =
0, 1, . . . , |Lfull|}, with L0 as the control. Let the set of second stage leaf doses be `full =
{ljk : k = 1, . . . ,Mj, for j = 1, . . . , |Lfull|}. For any dose d, we use X¯d to denote the sample
mean (or we use X¯i,d when it is necessary to specify the stage, i). Let Yd = X¯d − X¯0 (or
Yi,d = X¯i,d − X¯i,0) be the observed effect relative to the control. We let µd be the treatment
mean for d and θd = µd − µ0 be the treatment effect. We assume there are n1 patents per
arm for stage 1 and n2 per arm for stage 2, so that V1 = σ
2/n1 and V2 = σ
2/n2 are the
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for the first and second stages, respectively. This simplification captures the key features of
the score based method.
In general, let θdj be a measure the superiority of treatment dj over control d0 and let
it be expressible as µdj − µd0 , where µdj is the measure of the level of response in group j.
Then, as shown by Scharfstein, Tsiatis, and Robins, [34], the score function for θdj , Zdj , can
be expressed as V(µˆdj − µˆd0) where µˆdj is the maximum likelihood estimate of µdj and V is
the observed information for the comparison. This gives an immediate interpretation of the
score vector.
In large sample behavior, the relevant mathematical result is the weak convergence of the
normalized score vector under a local alternative sequence. If θn = θ0+hnn
−1/2, hn → h ∈ Rk,
and appropriate regularity conditions hold (quadratic mean differentiable family), then under
P nθn , Zn
d→ N(I(θ0)). For details and exact notation see Lehmann [21], Chapter 12. In the
literature of sequential trials [14, 39, 45], this is often written less rigorously. In the case of
equal observed information per group, with VL0 = VL1 = · · · = VLJ = V as the observed
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We give a first definition of the Horizontal Test.
Definition 1 In the above setting, consider the set of doses D = L ∪ `, with L ⊂ Lfull, and
` ⊂ `full. A horizontal test of HD : θd = 0, ∀d ∈ D is given by these steps:
1. Set cD according to
PrHD(max{n1Y1,L + n2Y2,L : L ∈ L, kDn2Yl : l ∈ `} ≥ cD) = α





2. Following the first stage, decide which set S ′ = L′ ∪ `′, with L′ ⊂ L, and `′ ⊂ `, to
study in the second stage. Set c′D such that:
PrHD(max{n1Y1,L + n2Y2,L : L ∈ L, kDn2Yl : l ∈ `} ≥ cD|y1,L : L ∈ L)
= PrHD(max{n1Y1,L + n2Y2,L : L ∈ L′, kDn2Yl : l ∈ `′} ≥ c′D|y1,L : L ∈ L)
3. Perform the second stage and reject HD iff
max{n1y1,L + n2y2,L : L ∈ L′, kDn2yl : l ∈ `′} ≥ c′D
This test is valid by Mu¨ller and Scha¨fer’s principle. Let R be the event of rejection of
HD in the procedure restricted to D
′=D, and let Ra be the event of rejection of HD in the
procedure allowing full data dependent adaptation. Under HD, with the first stage data
written as X :
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Pr(R) = E{Pr(R|X )} = E{Pr(Ra|X )} = Pr(Ra) = α. (4.1)
Standard assumptions that are implicit in other adaptive designs, for instance that the
second stage data be conditionally independent of the first stage given the adaptation deci-
sion, and that the adaptation rule used to select D′ be measurable with a countable range
must also be made here. These are discussed by Jennison and Turnbull, and by Liu, Proschan,
and Pledger [15, 26]. The preferred method to calculate adapted c′D values is by Monte Carlo
simulation.
The name “Horizontal” refers to the way the test first pools data from different treatment
groups (horizontally) across stages before taking a maximum. This is in contrast to the
formulation of Section 3.2, where data were reduced (vertically) to stagewise P -values and
later pooled (horizontally) using combination rules.
4.3 Characteristics of the Horizonal Test
Here we argue that the Horizontal Test is a good choice for use in a Limb-Leaf Design from
two perspectives. One is the evaluation of its performance under fixed adaptation plans
that are similar to those we would expect to follow in a Limb-Leaf Design. The other is the
graph of its conditional error function. Both perspectives are informative in showing that
the efficiency of the Horizontal Test is close to that of the efficient combination test based
on the Weighted Rule and that the robustness of the Horizontal Test exceeds that of the the
robust combination test based on the Maximum Rule.
Consider a two stage study with two doses, d1, and d2. Let d1 be studied in the first stage
with options to promote it to the second stage (sustain), promote it and add d2 (sustain with
addition), discontinue it (discontinue), or discontinue it and switch to d2 in the second stage
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(switch). Let the effects for d1 and d2 be θd1 and θd2 , respectively. We do not assume that
d2 is a leaf from limb d1. We need to allow its effect to vary.
To be specific, let there be 25 patients per arm (including the control) in each stage.
Outcomes are normally distributed with standard deviation σ. We will consider two adap-
tation plans. Plan 1 is to sustain d1 if Y1,d1 ≥ σ/4 and otherwise to switch to d2. Plan 2 is to
sustain d1 with addition if Y1,d1 ≥ σ/4, and otherwise to discontinue the study. These rules
mimic what would occur in an actual trial, where adequate performance of a treatment arm
would lead to further study, and poor performance would cause interest to shift to other,
potentially more effective dose levels.
The first case we present is where d1 is effective, µd1 ≥ σ/2. Plan 1 is used for the adap-
tation. We report the power to confirm the effect of d1. It is seen that the Horizontal Rule
(Horizontal Test) outperforms the robust Maximum Rule and does not suffer significantly
in performance over the most important range of powers compared to the Weighted Rule.
Sustain after good first stage results for n = 25










Horizontal .68 .85 .94 1.00
Maximum .58 .80 .92 0.99
Weighted .74 .87 .95 1.00
The next case is where the first dose is ineffective and a switch is appropriate. Plan 1 is
still followed. We report the results over a range of means. Note that lower powers are due
to the effect of the lower cumulative sample size on d2. This is correctable by increasing the
second stage sample size to achieve any desired conditional power.
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Switch after poor first stage results for n = 25, θd1 = 0










Horizontal .38 .51 .63 .77
Maximum .35 .49 .61 .77
Weighted .19 .30 .40 .57
The Horizontal Rule outperforms the robust Maximum Rule. The performance of the
Weighted Rule is poor, and despite its ideal performance in the case of sustaining a limb
dose, the power in case of a switch is so low that the Weighted Rule is not acceptable.
Fortunately, the Horizonal Rule has similar efficiency and is far more robust.
We now allow more than one dose in the second stage under Plan 2. Assume both d1
and d2 are effective. We report the power to confirm either effect over a range of means.
Sustain and add after good first stage results for n = 25, θd1 = θd2 = θ







Horizontal .69 .87 .95 0.99
Maximum .62 .81 .92 0.99
Weighted .75 .88 .96 1.00
The Horizontal Rule again outperforms the robust Maximum Rule and does not suf-
fer significantly in performance over the most important range of powers, relative to the
Weighted Rule.
We also consider the power under Plan 2 to confirm the effect on d1 when the added
dose, d2, is not effective. We set θd2 to 0 and allow θd1 to vary.
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Sustain and add after good first stage results for n = 25, θd2 = 0










Horizontal .66 .84 .94 0.99
Maximum .56 .76 .90 0.99
Weighted .68 .85 .94 1.00
Favorable properties of the Horizontal Rule can be seen from the graph of its conditional
error function in relation to the conditional error functions of the other rules (see Figure
1, Appendix). We recall that the value of the conditional error function CEF(P1) for a
P -value combination test is the greatest second stage P -value that could lead to rejection.
Assuming a (conditional) uniform P2, CEF(P1) equals the conditional probability of a type
1 error, given the first stage P -value. The CEF can also be expressed in the Z1, Z2 plane. In
general, the Horizontal Rule is not expressible in terms of a combination rule for P -values;
rigorously its conditional error function is undefined. However, under Plan 1 of the previous
simulation study, the conditional probability of a type 1 error given the first stage results can
be computed. This conditional error function coincides with that of the robust Maximum
Rule, when first stage results are poor. When first stage results are good, its conditional
error function bends to approach that of the efficient Weighted Rule. This behavior is highly
desirable.
From one point of view, the Horizontal Rule provides a well motivated and appropri-
ate conditional error function for this application. However, further simulation studies (not
shown) demonstrate that the new structure of the Horizontal Rule also adds to its perfor-
mance. This can be seen even in the two treatment case. To demonstrate, we compared
the Horizontal Rule to the combination rule of stagewise P -values whose conditional error
function was set equal to the previously described conditional error function of the Horizon-
tal Rule. The results were positive. For instance, in the case of sustaining and adding after
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good first stage results, if θd1 =
5σ
8
and θd2 = 0, the power of the Horizontal Rule was ap-
proximately .84 while the power of the stagewise constructed substitute was approximately
.81.
Given these results, we now wish to formulate a Limb-Leaf Design using Horizontal Tests,




Further Theory of Closed Testing
Procedures
Here we give some results to justify our approach to produce the Limb-Leaf Design. Several
issues to discuss are: the choice of a closed testing procedure as the means to control the
FWER, what kind of optimality is achievable, and the validity of a closed testing procedure
based upon the Horizontal Rule. As an aside, an alternate derivation of the Ho¨lm Procedure
is deduced from Proposition 1.
Proposition 1 Any multiple testing procedure B concerning hypotheses {Hj : j = 1, . . . , J},
with strongly controlled familywise error rate α is “dominated” by a closed testing procedure
C with the same familywise error rate. (By this we mean that for any false Hj, the probability
of rejecting Hj in C is greater than or equal to the probability of rejecting Hj in B, regardless
of the underlying parameter configuration.)
Proof: For each S ⊂ {1, . . . , N} define the test C∗S of HS =
⋂
j∈S Hj as 1 if Hj is rejected in B, for some j ∈ S;0 otherwise
and let Hj be rejected in the multiple testing procedure C∗ iff C∗S rejects HS, ∀S 3 j.
This means that C∗ is a closed system of tests such that Hj is rejected by C∗ iff Hj is rejected
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by B. To verify that each C∗S ∈ C∗ is of level α, we refer to the strong familywise error
rate control of B. Assume that for given S, all j ∈ S are true. Then Pr{C∗S = 1} ≤
Pr{Reject some true null hypothesis in B} ≤ α
Now the individual tests, C∗S : S ⊂ {1, . . . , N}, may be improved as follows: If supθ∈HS Pr
{C∗S = 1} ≤ α then we may add to its critical region, RC∗S , a (possibly null) set AS of the
sample space so that its size becomes α. Let the test CS be constructed from C
∗
S for each
S in this manner, with rejection region RCS = RC∗S ∪ AS. The resulting tests form a closed
procedure, C, and since, for any false Hj, {∩C∗S rejects, ∀S 3 j} ⊂ {∩CS rejects, ∀S 3 j},
Pr(C∗ rejects Hj) ≤ Pr(C rejects Hj). Thus C dominates C∗, and also B.
This observation allows us to think of the closed testing procedures in the multiple testing
problem as analogous to an essentially complete class in a decision theory problem. We do
not need to look beyond this class in our choice of test procedure and can instead focus on
choosing an efficient and convenient procedure within this class.
A desirable property of a closed testing procedure is consonance.
Definition 2 The closed testing procedure C of hypotheses {Hj : j = 1, . . . , J} using tests
{CS : S ∈ S = 2{1,...,J}} is called consonant if rejection of any (composite) null hypothesis
HS by C implies the further rejection of some hypothesis HT , T ⊂ S.
In a consonant procedure, rejection of the global null in its specific test ensures (by recur-
sion) that at least one component hypothesis will be rejected in the overall procedure. A
trivial example is as follows: Consider hypotheses {H1, · · · , HJ} with associated P -values
{P1, . . . , PJ}. Let a closed testing procedure be formed by testing composite hypotheses
using the Bonferroni correction applied to each component. Then, since α
J
< α
J−1 < · · · < α1 ,
it is clear that this procedure is consonant.
Proposition 2 This dominating procedure may be chosen to be consonant.
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Proof: Consider the procedure C given above. The previous construction may be applied
again to generate a procedure C ′. It then follows that C ′ is consonant and rejects any Hj iff
this hypothesis is rejected in C.
It may not be possible (or useful) for an adaptive procedure to maintain consonance under
every possible adaptation. However, this result is still interesting.
The next question is what kind of optimality is achievable. Proposition 3 shows that
even in simple cases there does not exist a UMP multiple testing procedure.
Proposition 3 If we define a UMP multiple testing procedure of familywise error rate α
for a given set of hypotheses as one that dominates every other multiple testing procedure of
level α, then no UMP multiple testing procedure exists (even) for testing the means of two
independent normal populations.





, where ~θ = (θ1, θ2)
′ and I2 is the identity
matrix of dimension 2. The hypotheses of interest are H1 : θ1 ≤ 0 and H2 : θ2 ≤ 0. Let the
corresponding alternatives be H1a : θ1 > 0 and H2a : θ2 > 0.
Assume that a UMP multiple testing procedure B of familywise error rate α exists.
Then it may be chosen as a closed consonant testing procedure consisting of size α tests,
ψ1, ψ2, and ψ{1,2}, of H1, H2, and H{1,2} = H1 ∩ H2, respectively. Let φ1 denote the UMP
size α test of H1 versus H1a, and let φ2 denote the UMP size α test of H2 versus H2a. Let
the rival procedure B1 test H1 and H{1,2} by φ1 and H2 by φ2. Similarly, let the procedure
B2 test H2 and H{1,2} by φ2, and test H1 by φ1. We produce a contradiction as follows:
Consider the alternative (θ1 = θ
′
1 > 0, θ2 = 0). Then, since B dominates B1, Pr(ψ{1,2} =
1) = Pr(φ1 = 1). Then, from the uniqueness of UMP tests for normal models, ψ{1,2} = φ1
a.s. must be satisfied. Now consider alternative (θ1 = 0, θ2 = θ
′
2 > 0). For B to dominate
B2, Pr(ψ{1,2} = 1) = Pr(φ2 = 1), and ψ{1,2} = φ2 a.s. must be satisfied. These two necessary
conditions on B are not consistent.
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Seeing this limitation, our target will be to produce a closed testing procedure with a
favorable tradeoff between efficiency and robustness. The performance should hold over a
range of alternative configurations of interest and over plausible adaptations.
As a first step, we show that a closed testing procedure built from the Horizontal Rule
will be valid.
Proposition 4 Adaptations of a closed testing procedure that preserve the conditional type
1 error rate of each constituent test maintain the strong control of the familywise error rate
of the procedure.
Proof: Let S∗ be the set of the indices of all true null hypotheses and let HS∗ =
⋂
j∈S∗ Hj.
Given the closed structure, it still holds in the adapted version of the procedure that
{Reject any true null hypothesis} ⊂ {Reject HS∗} and P ( Reject any true null hypothesis)
≤ P (Reject HS∗). Equation 4.1, Section 4.2, holds for any adaptive test that preserves its
conditional type 1 error rate. Therefore, the adaptive test of HS∗ is valid and the familywise
error rate of the procedure as a whole is controlled at α.
Example: To show that these observations are useful beyond Limb-Leaf Designs, we give
an example of an alternate derivation of a classic sequential test procedure from Proposition
1.
The Ho¨lm Procedure [11] is a versatile and powerful procedure for the following situa-
tion: There are J null hypotheses, H1, H2, . . . , HJ that are tested separately with statistics
Y1, Y2, . . . , YJ , respectively. These test statistics are assumed to tend toward greater val-
ues when their corresponding hypotheses are not true. The critical level αˆk(yk) for the
outcome yk of statistic Yk then equals supHk Pr(Yk > yk). The observed levels (P -values)
R1, R2, . . . , Rn, defined by Rk = αˆk(Yk), are ordered as R
(1) ≤ R(2) < · · · ≤ R(J). Let their
corresponding hypotheses be H(1), . . . , H(J). For given α, the procedure is as follows:
Step 1: Let j = 1.
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Step 2: Is R(j) ≤ a
J−j+1?
Step 3: If no, accept H(j), ..., H(J), and end the procedure.
If yes, reject H(j).
Step 4: If j = J , end the procedure, otherwise let j = j + 1 and go to
Step 2.
Proof: Consider the Bonferroni tests that compare each Rj to
α
J
. For any S ⊆ {1, . . . , J}
define the test C∗S that rejects iff Hj is rejected in its Bonferroni test for some j ∈ S. Each C∗S
is then a level α test of HS, and any Hj is rejected in the Bonferroni test iff C
∗
S rejects ∀S 3 j.
This defines C∗, consisting of {C∗S : S ⊆ {1, . . . , J}} as a closed testing procedure that rejects
an individual hypothesis iff this hypotheses is rejected in the Bonferroni Procedure.
We note that the size of each C∗S ∈ C∗ is only |S|J α, where |S| = m. Following the method
of Proposition 1, the size of each test can be increased to α in a way that increases the
overall power. In this particular case, let the test be enlarged as follows: for any C∗S with
|S| = m, derive the Bonferroni tests with level α
m
of each Hj, j ∈ S. Let CS reject HS if any
of these m component tests rejects. The result is an improved closed testing procedure C
that is strictly more powerful than the original procedure C∗.
Finally, it is necessary to show that rejection of a component hypothesis in C is equivalent
to its rejection in the sequential Ho¨lm Procedure. Let us assume that H(1), . . . , H(j) are
rejected sequentially. Consider H(1), with obtained level R(1) < α
J
. This forces the rejection
of the global null, and of the null hypothesis by every CS with HS ⊂ H(1). Therefore H(1) is
rejected in C. Similar reasoning applies to H(2): the global null has already been rejected,
and every remaining HS ⊂ H(2) must satisfy |S| ≤ J − 1. Since R(2) < αJ−1 , each such
hypothesis will be rejected in C. By recursion, we continue to consider hypotheses in this
order until H(j) is reached. At this last stage, every HS ⊂ H(j) yet to be rejected now
satisfies |S| < J − j + 1. Since R(j) < α
J−j+1 , these hypotheses will all be rejected in C.
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Next, let us assume that H(j+1) is not rejected sequentially. This means that R(j+1) ≥
α
J−j . So long as j < J , there exists an S such that HS ⊂ H(j+1) and |S| = J − j. Since
R(j+1) ≤ R(j+2) ≤ · · · ≤ R(J), the rejection of this hypothesis in C would require R(j+1) <
α
J−j , contrary to our assumption. Therefore, rejection of a hypothesis in the sequential
procedure occurs iff rejection also occurs in the closed procedure C, and the two procedures




A Basic Version of the Limb-Leaf
Design
Here we show a basic version of the Limb-Leaf Design using the Horizontal Rule. In Section
6.1 we present the plan of the experiment and make a restriction on the adaptation procedure.
In Section 6.2 we characterize the dose response curves for which we intend to use the Limb
Leaf Design as those with “locatable” effects. The advantages of using the Horizontal Rule in
a Limb-Leaf Design are demonstrated by simulation in Section 6.3. Further components such
as a template adaptation strategy, early stopping for futility, optimization of parameters, and
sample size adjustments are discussed in Chapter 7.
6.1 Description of the Design
Consider that the set of limb doses Lfull and the set of leaf doses `full are to be investigated.
The Limb-Leaf experiment consists of four steps: (1) a first stage where n1 patients are
randomized to each limb and to the control; (2) an interim analysis where it is decided
which, if any, limb to promote to the second stage and which leaf doses to add; (3) a second
stage where n2 patients are randomized to each limb or leaf dose of interest and to the control;
and (4) a final analysis, where dˆ∗ is selected and Horizontal Tests are used in a closed testing
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procedure to control the familywise error rate for the decision on the efficacy of dˆ∗ at level
α. It should be the best performing limb that is promoted and the best performing second
stage dose that is recommended as dˆ∗. This is a safe assumption; as in other designs, if a
different selection is made, the resulting procedure is conservative.
We set a restriction on our search strategy to improve the convenience of the Horizontal
Test in a Limb-Leaf Design: of the limbs, at most one can be promoted to the second
stage, and of the leaves, at most a prespecified number are allowed to be added. To allow
exploration on both sides of a promising region we prefer to set this number, n|`|, to 2.
In the above setting, consider the set of doses D = L ∪ `, with L ⊂ Lfull, and ` ⊂ `full.
With n|`| = 2 and the distributional assumptions of Section 4.2, the Horizontal Test ΨD of
HD : θd = 0,∀d ∈ D is given by these steps:
Definition 3 For |` | ≤ 2:
















Here L∗ indicates the limb promoted to the second stage. To calculate cD we assume
L∗ = argmax L∈LY1L and set the rejection probability under the null to α. If a different
promotion decision is made, the test will be conservative.
2. Based on the first stage results, decide which L ∈ L, if any, to promote and which
subset `′ ⊆ ` to include in the second stage. Calculate c′D to preserve the conditional
rejection probability at Step 3 as in Definition 1.











If no limb has been promoted, the corresponding term is left out.
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For |`| > 2 the restriction on the number of leaves requires a modification. Let `=
{l1, l2, ..., l|`|}, ordered arbitrarily.












L∗, ED, kD, and cL,` are defined as above and the value of cD does not depend on the
arbitrary choices of l1 and l2.
2. Based on the first stage results, decide which limb, if any, to promote and which set
`′ ⊆ `, |`′| ≤ 2, to study. Calculate c′D to preserve the conditional rejection probability
at Step 3 as in Definition 1. When some L∗ ∈ L is promoted and |`′| = 2, c′D will be
unchanged from cD.











(excluding the term involving L∗ if no limb appears in the second stage).
Proposition 4, Chapter 5, allows the use of this test in a closed procedure of given familywise
error rate α.
To aid in computation, we classify the tests involved in a rejection decision in the closed
testing procedure and give a bound to the number of tests that are sufficient to consider. This
bound is independent of what adaptations have been performed. Consider the confirmation
of activity on a leaf l∗ in the overall procedure, and all of the tests that need to be applied at
the end of the experiment. Any of these corresponds to a set of doses that may be denoted
as D∗ = {L∗ ∪ `∗}. Possible values |L∗| may take are 0, . . . , |Lfull|. Further, there exists the
indicator B ∈ {0, 1} of whether a promoted limb, L∗, if one exists, belongs to L∗. Finally,
52
there is the number of leaves considered, |`∗|. We say that a test ΨD1 concerning the dose
set D1 dominates the test ΨD2 concerning D2 if a rejection by ΨD1 implies a rejection by
ΨD2 . Obviously, two tests may be equivalent by dominating each other. The bound is based
on constructing a sufficient collection of tests associated with l∗ such that any other test
involved in the inference on l∗ is dominated by a member of this collection. The size of this
collection is then shown to be linear in |Lfull| and n|`|.
We note from Definition 3 that for any D∗ = L∗ ∪ `∗ with |`∗| > 2, ΦD∗ is dominated by
(equivalent to) a ΦD† for some D
† with the same L∗ and B, but with |`∗| = 2. We therefore
eliminate the tests of all D∗ with |`∗| > 2 from our sufficient collection.
A class of sets {D∗}|L∗|,B,|`∗| is determined by any chosen values of |L∗|, B, and |`∗|. For
a given D∗ within that class, let τ be the number of elements of `∗ that appear in the second
stage. Since the total collection of all hypotheses to consider in the closed testing procedure
has the form of a Cartesian product between all collections of limb doses and all collections
of leaf doses, it is possible to extremalize over each dimension independently. Thus, for
{D∗}|L∗|,B,|`∗| we may select a D+ = L+ ∪ `+ such that τ is maximized and the first stage
results, YLj for Lj ∈ L+ are minimized. Then, by Definition 3, ΨD+ dominates every other
member of this class.
There are at most |Lfull| + 1 possibilities for |L∗|, at most two possibilities for B, and
n|`| possibilities for |`∗|. Therefore, the bound on the size of a sufficient class of tests is
2(|Lfull| + 1)n|`|. The same reasoning applies to any selected limb, L∗, except that it is not
necessary to consider the case B = 0, and the bound is (|L|+ 1)n|`|.
It is possible to reduce the sufficient set of tests further, however the form of this bound
already has an important property: it is independent of the total number of leaves |`full|,
and only depends on the largest number that can be added, n|`|. A consequence is that
|`full| can go to infinity, without affecting the bound on the number of tests in the sufficient
collection. This means that “tuning” of second stage limbs may be performed: an arbitrarily
dense collection of leaf doses may be specified, the second stage additions may be chosen to
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lie anywhere within this collection, and the upper bound on the number of tests to perform
for final inference is unaffected.
6.2 Locatable Effects in Dose Response Profiles
The assumption we will make in the Limb-Leaf Design is that the choice of the limbs, leaves,
and initial parameters is appropriate for an adaptive selection strategy to access a dose
level with the desired effect. We wish to state this more formally. Let the limb-leaf system
S = {Lfull∪`full} be as described in Section 2.1 and let the parameter vector ~δ be the vector of
constants (δ1, δ2, δ3, δ4), with δ1 < δ2 < δ3 < δ4. Let D denote the underlying dose response
curve and let the effect for any specific dose d be θd. The need of the Limb-Leaf Design is
that the desired level of effect (δ4) be locatable with respect to S and ~δ.
Definition 4 The dose response curve D is said to have a locatable effect with respect to S
and the vector ~δ if two conditions are satisfied:
1. Existence of a promising region: The limb doses may be classified as “promising” or
“unpromising”, according to whether θLi > δ2 or θLi < δ1 for each i ∈ {1, ..., |Lfull|},
with at least one θLi > δ1.
2. Existence of desired effects within promising regions: For any promising limb dose Li,
all d ∈ {Li, li,1, . . . , li,Mi} can be classified as having the desired effect, if θd > δ4, or
lacking the desired effect, if θd < δ3. For any promising Li, there is at least one d ∈
{Li, li,1, . . . , li,Mi} with the desired effect.
Given the seeming strength of these assumptions, we illustrate several of the common
situations in which they apply. Figure 2a (see Appendix) shows examples of locatable effects
on either limb or leaf doses, with the limb-leaf system and the vector of effects held constant.
Figure 2b shows departures from locatability caused by misspecifications of limb and leaf
locations or by misspecifications of parameters. It is important to note that any of these
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departures could be put in a form with a locatable effect by a different choice of the limb-
leaf system and/or a different choice of parameter vector. In Section 8.2.2 we examine the
effects of departures from these assumptions or misspecifications of parameters in a fully
implemented Limb-Leaf Design and show that the consequences are often mild.
6.3 Simulation Results
Here we investigate the performance of the basic version of the Limb-Leaf Design using
Horizontal Tests and compare it with procedures using the Weighted Rule or Maximum
Rule. The goal is to show that the properties of the Horizontal Test seen in Section 4.2 lead
to a favorable balance between robustness and efficiency in the multiple testing procedure.
There are many aspects of the performance to consider: power on limb doses as well as
leaf doses must be investigated under different numbers of limbs and leaves, parameter
configurations, and adaptation decisions. The simulation studies reported here consist of
several cases. These have been chosen because they are the most plausible in our intended
use of the Limb-Leaf design and the most revealing of the performance characteristics. These
examples all deal with locatable effects.
Specifically, there are two dimensions to explore in terms of power: power to confirm the
effect on a limb, and power to confirm the effect on a leaf dose. There are three possible
types of adaptations: to forward a chosen limb without addition of leaves, to forward with
addition of leaves, and to promote leaves without the corresponding limb. These adaptations
are to be made data dependently; however, we consider fixed adaptation strategies for this
section in order to isolate the performance of the multiple test procedure from that of the
adaptation rule.
The eight simulation studies presented in Table 1a cover different adaptations with
|Lfull| = 2, or 3, and n` = 2. The generic parameters chosen for this study are n1 = n2 = 100,
and V1 = σ
2/n1 = V2 = σ
2/n2 = .01; parameter optimization and other components are
deferred to Chapter 7. The powers reported here allow us to compare the multiple testing
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procedures using the Horizontal (H), Weighted (W), and Maximum (M) Rules and to con-
firm that the results are consistent with those seen in Section 4.3
Scenario I (Power on a Leaf with Promotion): This scenario investigates the
power to confirm an effect on a leaf dose in the case of promotion of a first stage limb
and addition of two leaves. The situation for |Lfull| = 2 is as follows: Lfull = {L1,L2}, and
`full = {l1,1, l1,2, l2,1, l2,2}. The corresponding vectors of effects are {δ1, δ2}, and {δ1, δ1, δ2, δ4},
with δ1 = 0, δ2 = .2 = 2
√
V1, and δ4 allowed to vary. The selection rule is the following: At
the first stage, the limb with greater observed effect is promoted and its leaves are added.
At the end of the second stage, the arm with the greatest observed second stage effect is
selected and a multiple testing procedure is conducted to confirm the effectiveness of that
dose. Power is defined as the probability to correctly identify and confirm the true effect on
leaf l2,2.
Similarly, for |Lfull| = 3, Lfull = {L1,L2,L3} and `full = {l1,1, l1,2, l2,1, l2,2, l3,1, l3,2}. The
vector of limb effects is {δ1, δ1, δ2} and the vector of leaf effects is {δ1, δ1, δ1, δ1, δ2, δ4}, with
δ1 = 0, δ2 = .2, and δ4 allowed to vary. At the first stage, the limb with greatest observed
effect is promoted and its leaves are added; at the end of the second stage, the arm with the
greatest observed second stage effect is selected and a multiple testing procedure is conducted
to confirm the effectiveness of that dose. The power is the probability to correctly identify
and confirm the effect on l6.
This scenario corresponds to one of the most likely implementations of a Limb-Leaf De-
sign: after first stage results, it is decided to promote the best performing limb and to explore
two leaves around it.
Scenario II (Power on a Leaf Without Promotion): This scenario covers the case
in which leaves are explored but the underlying limb is discarded. The arms and associated
parameters are as in Scenario I, and the adaptation rule is that two leaf doses are added
56
upon the best performing limb without promotion of that limb. The power reported is the
probability to correctly identify and confirm the true effect on leaf l2,2 (or l3,2).
This scenario is relevant because first stage results may not be sufficiently promising on
the best performing limb to promote it, but further exploration may still be worthwhile.
This strategy represents the belief that one of the leaves outperforms the limb, and accepts
the risk of only exploring these leaves in order to conserve resources.
Scenario III (Power on a Limb with Promotion): This Scenario concerns the
confirmation of an effect on a limb dose when promotion occurs along with the addition of
two leaves. For |Lfull| = 2, Lfull and `full have vectors of effects {δ1, δ4}, and {δ1, δ1, δ2, δ2},
respectively, with δ1 = 0, δ2 = .2, and δ4 allowed to vary. The adaptation rule is as in
Scenario I: At the first stage, the limb with greater observed effect is promoted and its leaves
are added. At the end of the second stage, the arm with the greatest observed second stage
effect is selected and a multiple testing procedure is conducted to confirm the effect of that
dose. The power given here is the power to correctly identify and confirm the desired effect
on L2.
For |Lfull| = 3, Lfull and `full have vectors of effects {δ1, δ1, δ4} and {δ1, δ1, δ1, δ1, δ2, δ2},
respectively, with δ1 = 0, δ2 = .2, and δ4 allowed to vary. The selection rule is as in Scenario
I and the power explored is the power to correctly identify and confirm the effect on L3.
This scenario is a likely outcome of a Limb-Leaf Design: the desired signal was on one
of the original limbs, however additional exploration was undertaken. While this kind of
unnecessary exploration should be avoided with high probability, good performance in this
case will be required.
Scenario IV (Power on a Limb Without Addition): Here we consider confirmation
of an effect on a limb dose when leaves are not added. For |Lfull| = 2 (or |Lfull| = 3) the
vector of the effects corresponding to Lfull is {δ1, δ4} ({δ1, δ1, δ4}), with δ1 = 0 and δ4 allowed
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to vary. The selection rule is that the best performing limb is selected at the end of the
first stage, and promoted without addition to the second stage. The powers of the different
multiple testing procedures to confirm the desired effect are reported in the table.
This is one of the most relevant possibilities, because if sufficiently promising activity is
seen on a limb dose, no further exploration may be required. The goal would be to confirm
the desired level of activity on the selected limb while using as few additional resources as
possible.
Discussion and Conclusions: The conclusion of this simulation study is that the effi-
ciency and robustness properties of the Horizontal Test seen in Section 4.3 carry over to
the Limb-Leaf procedure as a whole. The procedure based on the Horizontal Test is an
advantageous compromise; it has far better power for confirming an effect on a leaf than the
procedure based on the Weighted Rule, and it suffers a smaller loss in power for confirming
an effect on a limb than the procedure based on the Maximum Rule.
In Scenario I, the procedure using the Weighted Rule has unacceptably low power (max-
imum of .68). The procedure based on the Horizontal Rule has the desired robustness and
outperforms the procedure based on the Maximum Rule by a small margin. The reported
powers plateau before reaching 1 because they are limited by the correct selection probability.
We consider it important to report power that combines the effects of the chosen multiple
testing procedure and the correct selection probability as our primary results. However, since
selection may occur by other criteria (cost, toxicity, or other factors) we also report power
figures in which the correct selections are imposed from outside (Table 1b). The conclusions
are the same.
Scenario II shows the same pattern as seen in Scenario I: the procedure based on the
Weighted Rule has a dramatic loss in power and the procedure based on the Horizontal Rule
outperforms the procedure based on the Maximum Rule. The influence of correct selection
can be seen because the powers do not reach 1, and by comparison with the results under
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enforced selection in Table 1b. As reported here, an inversion of the ordering of rules occurs
because the Maximum Rule seems to outperform the Horizontal Rule for some large values of
δ4. However, at these parameter values both procedures have already attained the maximum
power allowed by the correct selection probability, and the reported differences lie beneath
the margin of error based on 10,000 runs of the simulation.
In Scenarios I and II, the choice of δ1 = 0 is consistent with the search strategy, and with
the expectation that poor performance would exist on some dose levels. If δ1 < 0 were chosen,
the loss of power for the procedure based on the Weighted Rule would be exacerbated. This
loss of power diminishes with increasing δ1.
In Scenario III, the procedure using the Weighted Rule has the best power, and the
performance of the procedure using the Horizontal Rule is comparable. There is a modest
loss of power from the use of the Maximum Rule, particularly in the range of powers between
.7 and .9. The reported powers approach 1 because they are not limited by the correct
selection probability in the same way as they were in Scenarios I and II (correct selection
probability approaches 1 with large δ4). It is also important to note the large difference in
power between the limb and leaf doses. Further comments will be made below.
In Scenario IV, the procedure using the Weighted Rule again has the best power, and the
procedure using the Maximum Rule suffers a meaningful loss of power in the range of powers
between .7 and .9. The procedure using the Horizontal Rule comes closer to the efficiency of
the procedure using the Weighted Rule than the procedure using the more robust Maximum
Rule. As in Scenario III, there is a large difference between powers for limb and leaf doses.
Some discussion is needed of the cases presented and their simplifications. The case of
power to confirm a limb or a leaf when one leaf is added is not shown because it is less
common (though still possible) and the pattern of behavior is not qualitatively different
from Scenarios I and III; one can expect the power on a leaf to be slightly greater than that
reported in Scenario I, and the power on a limb to be slightly greater than that reported in
Scenario III. The parameter choices of n1 = n2 = 100, V1 = σ
2/n1 = V2 = σ
2/n2 = .01 are
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arbitrary; however, in any study it would be necessary to allow adequate first and second
stage sample sizes to achieve a high correct selection probability. Since selection can occur
in both stages, a severe imbalance between n1 and n2 would diminish overall performance
for all procedures.
A general feature of Limb-Leaf Designs is that the power to confirm an effect depends
on whether this effect is on a limb or a leaf and on how many leaves have been added.
The disparity in power seen in these simulations is foreseeable given the imbalance in total
sample size between the limb and leaf arms.. This imbalance is remedied in Chapter 7.
However, instead of proposing one-size-fits-all sample sizes and parameter values, this study
suggests that a conditional power implementation may be useful: initial values can be chosen
and possibly readjusted based on which scenario is carried out. The selection of initial
parameter values, their adjustment following an interim analysis, and other features such as
early stopping are discussed in the next chapter.
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TABLE 1a: PERFORMANCE CHARACTERISTICS
Scenario I Scenario II
|Lfull| = 2 |Lfull| = 3 |Lfull| = 2 |Lfull| = 3
δ4 W M H W M H W M H W M H
.20 .081 .112 .136 .051 .099 .130 .099 .160 .185 .065 .139 .168
.25 .140 .213 .245 .095 .190 .243 .180 .268 .285 .111 .234 .280
.30 .221 .312 .362 .142 .304 .361 .257 .396 .421 .163 .363 .405
.35 .321 .464 .502 .223 .430 .493 .356 .524 .563 .253 .497 .526
.40 .442 .614 .634 .299 .568 .620 .444 .651 .691 .317 .611 .640
.45 .540 .716 .741 .407 .666 .715 .523 .757 .775 .381 .712 .742
.50 .608 .802 .827 .487 .757 .785 .580 .833 .848 .467 .776 .795
.55 .639 .862 .880 .484 .811 .826 .666 .874 .890 .493 .817 .832
.60 .673 .893 .904 .528 .832 .844 .695 .901 .904 .536 .847 .853
.65 .683 .910 .912 .505 .854 .854 .690 .916 .912 .535 .857 .852
Scenario III Scenario IV
|Lfull| = 2 |Lfull| = 3 |Lfull| = 2 |Lfull| = 3
δ4 W M H W M H W M H W M H
.20 .189 .157 .180 .169 .150 .157 .535 .408 .481 .468 .375 .400
.25 .346 .291 .331 .325 .278 .310 .721 .594 .677 .675 .562 .610
.30 .535 .471 .526 .520 .449 .509 .861 .760 .823 .831 .732 .782
.35 .713 .654 .703 .700 .636 .693 .938 .879 .921 .930 .863 .903
.40 .842 .806 .841 .831 .791 .832 .981 .945 .976 .973 .938 .961
.45 .925 .902 .922 .921 .899 .922 .995 .981 .994 .993 .979 .987
.50 .967 .961 .966 .967 .956 .962 .999 .994 .999 .998 .994 .994
.55 .987 .985 .986 .985 .983 .987 1.00 .999 1.00 1.00 .998 1.00
.60 .996 .994 .995 .996 .994 .994 1.00 1.00 1.00 1.00 .999 1.00
.65 .998 .998 .999 .999 .999 .999 1.00 1.00 1.00 1.00 1.00 1.00
Based on 10,000 simulated experiments. Margin of error ≈ .006. Horizontal Rule and its competitor are shown in bold.
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TABLE 1b: ENFORCED SELECTION
Scenario I Scenario II
|Lfull| = 2 |Lfull| = 3 |Lfull| = 2 |Lfull| = 3
δ4 W M H W M H W M H W M H
.20 .211 .306 .228 .153 .313 .265 .218 .338 .265 .154 .338 .243
.25 .279 .385 .363 .187 .378 .373 .274 .406 .401 .199 .419 .352
.30 .365 .486 .480 .243 .486 .541 .344 .515 .522 .247 .513 .489
.35 .426 .566 .627 .326 .603 .653 .445 .661 .650 .328 .636 .629
.40 .549 .714 .757 .391 .720 .781 .547 .755 .777 .400 .739 .754
.45 .632 .809 .856 .479 .818 .869 .659 .839 .865 .492 .837 .852
.50 .666 .896 .914 .532 .896 .932 .706 .912 .934 .532 .912 .923
.55 .713 .946 .963 .575 .938 .967 .737 .955 .971 .580 .952 .960
.60 .752 .977 .981 .667 .972 .986 .741 .979 .985 .600 .979 .982
.65 .762 .989 .993 .631 .989 .995 .763 .991 .995 .630 .991 .992
Scenario III Scenario IV
|Lfull| = 2 |Lfull| = 3 |Lfull| = 2 |Lfull| = 3
δ4 W M H W M H W M H W M H
.20 .195 .152 .185 .390 .334 .350 .561 .451 .496 .524 .424 .437
.25 .353 .287 .336 .597 .489 .548 .738 .626 .690 .699 .570 .617
.30 .546 .471 .530 .753 .658 .726 .871 .771 .841 .855 .737 .784
.35 .711 .651 .708 .892 .806 .862 .946 .877 .932 .933 .863 .905
.40 .839 .804 .835 .955 .900 .947 .983 .950 .976 .980 .945 .968
.45 .920 .903 .915 .985 .954 .984 .996 .981 .995 .995 .978 .990
.50 .965 .958 .968 .997 .986 .995 .999 .995 .998 .999 .993 .997
.55 .986 .985 .987 .999 .996 .999 1.00 .999 1.00 .999 .999 .999
.60 .996 .995 .995 .999 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
.65 .999 .999 .999 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Based on 10,000 simulated experiments. Margin of error ≈ .006. Horizontal Rule and its competitor are shown in bold.
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Chapter 7
Additional Details of the Limb-Leaf
Design
The basic Limb-Leaf Design was described in Section 6.1. Here we introduce further compo-
nents that are necessary to implement it. We discuss (1) a reasonable exploration strategy,
(2) the use of an early stoping boundary for futility, (3) the choice of initial parameter values,
and (4) sample size adjustments at interim. These features are implemented in the example
of Section 8.2.
7.1 An Exploration Strategy
Assuming a dose response curve with a locatable effect as in Section 6.2, we propose a strat-
egy to explore the curve in order to identify and confirm a dose with this desired effect.
This is basic guidance; the actual strategy could differ based on the needs or character-
istics of any particular trial. Let θ∗ be the desired effect, and θˆ1,Lj , j = 1, . . . , |Lfull|, be
the estimated effects on limb doses from the first stage data. In the previous case of nor-
mal data with known variance, θˆ1,Lj = Y1,Lj = X1,Lj − X1,0. In the general score method,
Z1,Lj approx∼ N(θ1,LjV1,V1), and we may use θˆ1,Lj = Z1,Lj/V1. Let θˆ∗ be the effect estimate
on the selected limb L∗, and let ~a = (a1, a2, a3), with a1 < a2 < a3, express three levels of
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evidence as follows. The first component, a1, is the minimum threshold for the plausibility
of the desired effect within a neighborhood of L∗; if θˆ∗ < a1 further study is not indicated.
The second, a2, is the threshold for likely activity in the neighborhood of L
∗; if a1 ≤ θˆ∗ < a2,
exploration in the neighborhood of L∗ may be justified, without investigating L∗ itself. In
this case we may, for instance, discontinue L∗ but add two of its nearby leaves (as considered
in Scenario II, Section 6.3). The third level, a3, is the threshold for a strong indication of
the desired activity on L∗. If a2 ≤ θˆ∗ < a3 then we may choose to promote L∗ with addition
of two leaves (Scenario I/III). If θˆ∗ > a3, we may consider the evidence of activity on L∗
strong enough to not do any further exploration and concentrate on confirming this activity
with the minimum additional effort (Scenario IV). This proposed strategy is summarized in
the table below.
TABLE 2: SEARCH STRATEGY
I: θˆ∗ ≥ a3 Strong indication- Continue with L∗
without adding leaves.
II: a2 ≤ θˆ∗ < a3 Likely indication- Promote L∗ and
add two adjacent leaves.
III: a1 ≤ θˆ∗ < a2 Weak indication- Do not promote L∗, and
add two nearby leaves (further exploration).
IV: θˆ∗ < a1 Insufficient indication- Stop the study early and
do not spend additional resources.
Criteria for selecting ~a and the initial sample sizes per arm are discussed in Section 7.3. Each
decision (I-III) may be taken with desired conditional power as discussed in Section 7.4.
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7.2 Early Stopping
Early stopping contributes to the efficiency of the Limb-Leaf Design. Termination of an
ineffective treatment after a crude examination of the dose response is a main benefit of this
approach. To integrate this early stopping feature into the test procedure, the Horizontal
Test may be modified as follows.
Definition 5 (Horizontal Test with early stopping)




































Here L∗ indicates the promoted limb; ED, kD, l1, and l2 are as in Definition 3; and
c1D and c
0
D are such that the type I error probability is α under the assumption that L
∗ =
argmax L∈LY1L. The test then proceeds as in Definition 3.
We set the test of the global null according to Definition 5, with c0D = n1a1, and c
1
D
determined by the type 1 error constraint. This modification enforces the early stopping
given in Table II. Specifically, when the maximum of the first stage estimated effects is below
a1, the global test fails. Then, it will not be possible to reject any individual hypothesis in
the overall procedure and the study may end.
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It is also possible to modify other tests in the overall procedure according to Definition
5. However, we do not follow this route because gains in power from such modifications
are minimal. Such early stopping of tests for certain combination hypotheses can also be
questioned: Consider a test ΨD∗=L∗∪`∗ when some l ∈ `∗ is not associated with any L ∈ L∗.
Given that there is poor first stage evidence of effect on the limbs, it may or may not be
considered appropriate to terminate the test of the combination hypothesis. In the worst
case, a heavy bias towards early stopping based on the limbs could prevent the confirmation
of a true effect on l∗. In the case of the global null hypothesis, though, the early stopping
decision is well motivated.
7.3 Initial Parameter Values
The initial parameters that need to be set are ~a, n1L, n2L, and n2l. Here n1L is the sample size
per arm in the first stage, and n2L and n2l are the sample sizes per arm on the limb/control
and leaf doses in the second stage, respectively. In general we allow these sample sizes to
be different. We assume that the number of limbs, |Lfull|, is given. The choice of |Lfull| is
discussed in Section 8.1.
The choice of a1 is based on statistical and clinical concerns. Clinically, a1 must be a
meaningful threshold such that the investigators are willing to declare lack of efficacy if no
first stage estimated effect exceeds a1. Statistically, a1 should be such that the probability
of early stopping under the global null is sufficiently high (≈ .4 − .6). For |Lfull| = 3, a
reasonable value for this parameter would be .2 a3. Once this value is set and incorporated
into the test procedure, it may not be changed.
Conceptually, a2 is analogous to δ2 in Section 6.2. It is a level of response that is
sufficiently promising on a given limb for the desired level of activity to be plausible on
that limb (as opposed to only being plausible in the neighborhood). This parameter is
tentative, and may be revised following the first stage as part of the flexible adaptation
strategy. Reasonable initial values are in the range of .6 a3. An overestimate of a2 may
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throw away a promising limb, an underestimate could lead to the use of resources on a limb
whose performance is beneath the desired level.
The target level of activity, a3, should be chosen on clinical grounds. Statistically, an
overly optimistic initial value could lead to an underpowered study. An overly pessimistic
estimate could lead to an inefficiently large first stage sample size and a willingness to accept
a meaningfully lower treatment effect that the true maximum. This parameter is not fixed,
it can be modified using the first stage results.
For fixed choices of a1, a2, and a3, initial values for the parameters n1L, n2L, and n2l may
be set based on desired performance characteristics. In setting these initial values, we can
simplify by imposing additional constraints. We have set n1C , the sample size of the control
arm in the first stage, equal to n1L, and n2C , the sample size of the control arm in the second
stage, equal to n2L. We may also set n2L equal to ρ n2l, with ρ = 2, so that the total number
of patients per arm on a leaf dose equals that on a limb. The initial design then depends on
only one parameter (n).
This difference in sample size per arm between limb and leaf doses in the second stage
should be reflected in the form of the horizontal test. In Definition 3 (equal samples per
arm), Y2L∗ and Y2l were both weighted by n2 = n2L = n2l. Now, to reflect that the variance





, we set n′2l =
2n2Ln2l
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We make the corresponding change of n2l to n
′
2l in the adapted test as well.
The initial performance target can be expressed as the power to identify and confirm
locatable effects under two parameter configurations. The first places the desired effect
on one of the limbs; for |Lfull| = 2 and |`full| = 4, the vectors of effects on {L1, L2} and
{l1,1, l1,2, l2,1, l2,2} could be chosen as (0, a3) and (0, 0, a2, a2), respectively. Similarly, for
|Lfull| = 3 and |`full| = 6, the vectors of effects for {L1, L2, L3} and {l1,1, l1,2, l2,1, l2,2, l3,1, l3,2}
could be (0, 0, a3) and (0, 0, 0, 0, a2, a2). The second places the desired effect on the leaves:
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For |Lfull| = 2 and |`full| = 4, the vectors of effects on {L1, L2} and {l1,1, l1,2, l2,1, l2,2}
could be (0, a2) and (0, 0, a2, a3). For |Lfull| = 3 and |`full| = 6, possible vectors of effects
on {L1,L2,L3} and {l1,1, l1,2, l2,1,l2,2,l3,1, l3,2} are (0, 0, a2) and (0, 0, 0, 0, a2, a3). Reasonable
choices for power in these configurations are between .8 and .9, and the desired power on
a limb may be chosen to be greater than the power on a leaf (.9 versus .85, for instance).
In Section 8.2, we identify the “least favorable configurations with locatable effects” and set
the power in each case to be .9.
The power to identify and confirm the desired effect under the search strategy of Table
II is then an increasing function of n. To set an initial value, two approaches are suggested.
The simpler is to choose the minimum n, nmin, that meets the specified power conditions;
minimizing n is equivalent to minimizing the maximum of the total sample size, N . Since
a closed form solution is impractical, a direct simulation can be used to find this minimal
value. We call this a “minimax-style” parameter selection because it is not strictly a minimax
solution. A formal solution uses decision theory.
Assume a finite set Θ = {~θt, t ∈ T } of possible dose-response vectors, where each ~θt
represents a vector of effects across the limbs and leaves of the experiment. Let the prior
Π assign probability pt to each ~θt. For specific n, denote a decision rule corresponding to
the search strategy in Table II by δ∗n; a value of this rule then corresponds to an adaptation
decision based on the first stage data. The loss function is equal to the total sample size
expended in the entire experiment.
We may express the Bayes’ Risk of δ∗n, Rδ∗n , as the risk adjusted expected total sample
size:




where E~θt is the expectation with respect to the parameter vector
~θi, and each term of the
sum is evaluated by simulation. We may select n to minimize the Bayes’ Risk subject to the
above power constraints (restricted Bayes solution). For given δ∗n we may also evaluate the
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maximum risk over Θ and find the (restricted) minimax solution.
The optimality of any initial choice of n depends on prior assumptions. Sample sizes,
conditional power, and the relative balance between limb and leaf arms may be adjusted
after the first stage as shown in Section 7.4.
7.4 Sample Size Adjustment
Adjustment of sample sizes per arm based on conditional power is a useful feature of the
Limb-Leaf Design. One reason is that the sample size requirements to achieve desired condi-
tional power under the different adaptation decisions may differ substantially. For example,
in case IV of Table II there is only one dose level of interest for the second stage, whereas in
case III there are three. There is no need for correct selection in the second stage of case IV
and a lower n2L could be used to achieve a similar conditional power. Other reasons to use
conditional power include the desire to balance the powers to confirm limb and leaf effects,
and the need to adjust tests based on first stage performance. For example, if interim results
indicate that the choice of sample sizes based on the performance criteria stated in Section
7.3 is overly optimistic or overly pessimistic, sample sizes could be increased or decreased
respectively. Finally, it may be desired to alter the relative balance between limbs and leaves
from the default value ρ = 2. For these needs, we offer two types of modifications.
The first modification preserves the structure of the tests and the associated cutoff values.













The limb and leaf sample sizes may be increased by a constant factor c, and the resulting
test statistics can be labeled Y ′2L∗ and Y
′
2l, for l ∈ `′. Then, substitution of
√
c Y ′2L∗ for
Y2L∗ , and
√
c Y ′2l, l ∈ `′ for Y2l, l ∈ `′ in the original test does not alter the multivariate null
distribution or the resulting cutoff values. The alternative distribution changes in predictable
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way- each effect size θ is multiplied by
√
c. Simulation would be used to set the appropriate
sample size for desired conditional power. In this case only the parameter c needs to be
increased and the tests themselves do not need to be modified, until the desired conditional
power is reached.
In the second option it would also possible to modify ρ (or even change the balance
between limb and control sample sizes). Such a modification requires the computation of
new cutoff values based on the new covariance structure. One computation is sufficient,
though, because after new cutoff values are found, additional increases in sample size can
be expressed using a scaling constant, and the test statistics may be modified as previously
(without further changes to the covariance structure).
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Chapter 8
Comparison with a Standard
Approach
We have proposed that a Limb-Leaf Design can further improve on the benefits of adaptive
seamless designs in terms of the speed, efficiency, and streamlining of a drug development
program. In Section 8.1 we present some guidance on when to consider the Limb-Leaf Design.
In Section 8.2 we evaluate the performance and the assumptions of a limb-leaf strategy using
an explicit example. The benefits over a standard TSE-type design are seen to be large under
the global null hypothesis and also under the alternative when the first stage limbs are well
chosen to detect the desired level of effect.
8.1 Considerations for the Limb-Leaf Option
The Limb-Leaf Design is suited to cases in which it is necessary to identify an effect of the
desired level that may only exist in a narrow dose range, or when extracting the additional
benefits from a closer study of the dose response curve is considered worthwhile. This
could be the case in studying a new treatment for a severe disease if existing therapies are
ineffective or marginally effective, the benefit from any new treatment may only be small,
and the assumption of a monotonic dose response curve is not appropriate. Section 2.2
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identifies ALS research as an area in which this study design may be useful.
The appropriate use of a Limb-Leaf Design assumes an alternative D with a locatable
effect with respect to the chosen limb-leaf system S and parameter vector ~δ. Sources of
information on which to base this assumption include clinical judgement, animal models,
experience with related drugs, existing literature and case reports, pharmacodynamic models,
and Phase I studies within the same drug development program. Since there is greater
efficiency when the desired effect exists on a limb of S, it is further hoped that the prior
knowledge would give a significant chance of capturing a desired effect within L.
We do not foresee that the logistical and operational needs of a Limb-Leaf Design will be
substantially different from those of other adaptive seamless designs (as discussed by Maca
et al. [28]), except that the rate of recruitment may need to change depending on how many
doses are of interest in the second stage.
8.2 A Comparison by Simulation with a TSE-type
Design
We now show a comparison between a Limb-Leaf Design and a TSE-type adaptive seamless
design. For equivalent power, the Limb-Leaf Design has considerably lower risk adjusted ex-
pected sample size, with savings possible under both the null and alternative configurations.
The robustness of the Limb-Leaf Design’s performance to departures from assumptions and
misspecifications of parameters is investigated in Section 8.2.2.
8.2.1 Designs and Choices of Parameters
Consider that a new drug is under development and that the dose response curve may not
be assumed to be monotonic. It is hypothesized that the dose response curve is unimodal
and that the drug effect only exists in a narrow dose range. However, strictly increasing,
plateau, or constant profiles are also considered plausible.
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We will choose the simplest possible assumptions to emphasize the generality of this
example. Let the outcome x at any dose level di be distributed as N(θdi , 1), where θdi is a
level of effect with respect to the control and the desired level of effect is 1. Desired power,
defined as the probability to select and confirm an effective dose, is .9. The familywise error
rate with respect to the hypotheses of no effect at each dose will be controlled at α = .05.
As part of the specification of power, it is required to distinguish the desired effect from
effects that are 30 percent lower; an effect of .7 or lower will be considered unacceptable and
if it is mistakenly chosen when the desired effect (≥ 1) is present, the experiment will not
be considered a success.
Let a collection of 9 (generally unequally spaced) doses be considered appropriate to
identify the desired level of effect. Let these doses be organized as the limb-leaf system
S = {l1,1, L1, l1,2, l2,1, L2, l2,2, l3,1, L3, l3,2}, with the doses listed in increasing order. We are
willing to assume that under the alternative the desired effect of 1 is locatable, and that the
level of .625 corresponds to a promising effect as in Definition 4.
To finish the specification of the class of alternatives, we set ~δ = (.125, .625, .625, 1).
Although the choice δ1 = 0 would favor the Limb-Leaf Design, we are cautious in setting
a low “background level” for the effect of the treatment. The assumption of δ3 ↓ δ2 is a
simplification and a conservative choice. It would be correct to set δ3 to any value between
.625 and .7; however, the sample size requirements of the standard design were found to
increase rapidly with δ3. The lowest allowable value of δ3 is chosen in favor of the standard
design.
Examples of possible response levels ~θ = (θl1,1 , θL1 , θl1,2 , θl2,1 , θL2 , θl2,2 , θl3,1 , θL3 , θl3,2) corre-
sponding to these ordered doses include (.625, 1, .625, 0, 0, 0, 0, 0, 0), (.125, .625, 1, .625, .125,
.25, 0, 0, 0), and (.125, .125, .125, .400, .625, 1, 1, 1, 1), among others such as (0, 0, 0, .1, .25, .5,
.625, 1, 1.25). The robustness of the Limb-Leaf Design to departures from these assumptions
and/or misspecifications of parameters is given in Section 8.2.2. The global null is for no
effect at any dose.
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The TSE design [42] (described in Section 1.2) is modified to use normal outcomes as
described by Jennison and Turnbull in [18]. It has two stages; the first stage assigns subjects
to all nine treatments plus the control, and the second stage studies only the best performing
dose from the first stage against the control. There is the option to stop for futility using
a cutoff value after the first stage, and the final decision is made by whether the combined
measure of effect on the selected treatment exceeds a second cutoff value. The parameters
to set are: the first stage sample size per arm, n1; the second stage sample size per arm, n2;
the first stage futility boundary, y1; and the second stage cutoff value for efficacy, y2.
A strict implementation of the TSE design would use a least favorable configuration
of ~θlf= (.625, .625, .625, .625, .625, .625, .625, .625, 1), to set the power. However, given our
assumption that the alternative is in the subclass with locatable effects, this criterion should
be modified; to neglect the assumption of locatable effects leads to a sample size that is
an order of magnitude larger. By the argument given in [18], among all alternatives with
a single locatable effect within S with respect to ~δ, the power is (non-uniquely) minimized
by the vector of effects ~θloc = (.125, .125, .125, .125, .125, .125, .625, .625, 1), which we call
the “least favorable configuration with a locatable effect with respect to ~δ”. It is clear
(and easily verified by simulation) that the minimizers of power for two and three locatable
effects, (.125,.125,.125,.625,.625,1,.625,.625,1), and (.625,.625,1,.625,.625,1,.625,.625,1), lead
to higher power. We therefore set the power to .9 in the least favorable (locatable effect)
configuration.
We set this design’s parameters according to the original paper by minimizing the risk
adjusted expected sample size EpiN = piEHAN + (1 − pi)EH0N . Here HA represents the
alternative hypothesis of the least favorable (locatable effect) configuration, H0 represents
the global null hypothesis, and pi is a prior probability assigned to the alternative hypothesis.
Specifically, for given n1 and n2, y1 and y2 are set by the type 1 error and power constraints
(when solutions exist). Then EpiN can be minimized over n1 and n2. Optimization using
simulation of expected sample sizes for pi = .2 yields n1 = 36 and n2 = 11.
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We implement the Limb-Leaf Design as discussed in Chapter 7. The search strategy in
Section 7.1 is followed: the three limbs begin the first stage with options of early stopping,
addition, promotion with addition, or promotion without addition into the second stage
depending on the maximum observed effect at interim. In the case of promotion without
addition (when the desired effect is seen at the first stage), we adapt the second stage sample
size for the selected dose and the control according to Section 7.4. We let the adapted second
stage sample size be n2Ladapted =
1
2
n2L; a more exact modification could potentially lead to
greater efficiency.
Among all alternatives with a single locatable effect with respect to S and ~δ, the power for
an effect on a leaf is (non-uniquely) minimized by the vector of effects ~θ leaf = (.125, .125, .125,
.125, .125, .125, .625, .625, 1), which is the “least favorable configuration with a locatable leaf
effect with respect to ~δ”. As verified by simulation, the minimizers of power for two and three
locatable leaf effects, (.125,.125,.125,.625,.625,1,.625,.625,1), and (.625, .625, 1, .625, .625, 1,
.625, .625, 1), respectively, lead to higher power. Similarly, the least favorable configuration
with a locatable limb effect with respect to ~δ is ~θlimb = (.125, .125, .125, .125, .125, .125, .625,
1, .625). By enforcing power of .9 in the least favorable configurations for limb and leaf
effects, we meet the same power requirement that was used in the previous design.
The parameters to set for the Limb-Leaf Design are n1, n2L, and ~a. The choice of values
will again be based on minimizing the risk adjusted expected sample size, here expressed
as EpiN = pi1EHALN + pi2EHAlN + (1 − (pi1 + pi2))EH0N , with HAL and HAl as the least
favorable configurations for effects on the limbs and leaves, respectively.
In this study, we have divided pi = Pr(least favorable locatable effect) = .2 as pi1 + pi2,
where pi1 = Pr(least favorable effect on limb) = .1 and pi2 = Pr(least favorable effect on
leaf) = .1. In the standard design, there is no distinction between the doses that are labeled
as limbs and those that are labeled as leaves. There this expression reduces to the previous
form with pi = .2. The comparison measures for these two designs are therefore consistent.
We consider pi1 = .1 to be a conservative choice because a wise selection of limb doses could
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result in a higher pi1.
We set the parameters of the Limb-Leaf Design by minimization under constraints: We
set n1 = n2L =
1
2
n2l as suggested in Section 7.3, and choose a3 = δ4 because it is reasonable
to promote a limb without further exploration when the desired activity is already seen at
interim. According to the advice in Section 7.3, we select .6 as the probability for early
stopping under the global null. This determines a1 as a function of n1. Over the remaining
parameters, n1 and a2, we minimize the risk adjusted expected sample size subject to the
needs of .9 power for locatable effects on both the limbs and leaves (with respect to S and
~δ).
The results of numerical optimization are n1 = 42, n2 = 85, and ~a = (.175, .656, 1). This
restricted optimum is sufficient to demonstrate the favorable performance of the Limb-Leaf
Design. The performance of the competing designs given the above parameters is shown
below.
TABLE 3: COMPARISON OF EN VALUES
Least Favorable Locatable Configuration Limb-Leaf Standard (TSE) Design
Limb Effect 333.1 382.0
Leaf Effect 388.0 382.0
No Effect 254.3 364.8
Risk Adjusted 275.6 368.2
Results based on 10,000 simulated experiments.
The savings in risk adjusted expected sample size from using the limb-leaf approach is ap-
proximately 25%. The greatest savings occurs under the global null, where the investigation
of the dose response curve beginning with three limb doses rather than all 9 possibilities is
clearly efficient. We note that, in the case where the desired effect is on a leaf, the Limb-Leaf
Design’s expected total sample size slightly exceeds that of the standard design. The further
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exploration consumes approximately the same number of patients as were saved in the first
stage. From our point of view, this is an acceptable allocation of resources on an as-needed
basis.
8.2.2 Robustness to Deviations
It is necessary to study the robustness of the Limb-Leaf Design to deviations from the
assumed dose response profile. These results are condensed in Table III. As mentioned in
Section 6.2, such deviations can often be considered either as perturbations of a specified
dose response curve, or as misspecifications of the components of the vector ~δ. While it is
impossible to do a complete exploration of all deviations, robust behavior in several plausible
scenarios is important to show. Here we will fix the design parameters and vary the dose
response profile.
The first case we consider is the Step Function dose response with ~θS = (.125, .125,
.125, .625, .625, .625, 1, 1, 1). The effect is not locatable because Condition 2 of Definition
4 is not satisfied; however the effect would be locatable for a different choice of ~δ such
as (.625, .65, .7, 1). The performance is good under this alternative, with power=.963 and
EN = 334.3.
Two related cases are the Plateau dose response profile, with ~θP = (0, .16, .33, .5, .66, .83, 1,
1, 1), and the Monotone Increasing profile with ~θM = (0, .125, .250, .375, .500, .625, .750, .825,
1). The first has power .945 and expected sample size 333.6, the second has power .947 and
expected sample size of 367.2.
Of greater concern is the Bimodal profile represented by ~θBL = (.125, .225, .125, .625,
1, .625, .125, .125, .125) and ~θBl = (.125, .225, .625, 1, .625, .125, .125, .125, .125). Here the de-
crease in power is greater when the desired effect is on a leaf rather than a limb. This
is because of the risk of misdirecting the search strategy to explore the wrong region of
the dose response curve. Results for power and expected sample size for ~θBL are .925 and
335.2, respectively; for ~θBl the power and expected sample size are .885 and 388.7, respec-
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tively. A further increase in the magnitude of the secondary maximum, to ~θBL = (.125, .325,
.125, .625, 1, .625, .125, .125, .125) and to ~θBl = (.125, .325, .625, 1, .625, .125, .125, .125, .125)
yields power and expected sample size for ~θBL of .926 and 332.6, and power and expected
sample size for ~θBl of .847 and 389.9.
Also of concern are response profiles that are “Unimodal with Background” such as
~θUBL = (.225, .225, .225, .625, 1, .625, .225, .225, .225) and
~θUBl = (.225, .225, .625, 1, .625,
.225, .225, .225, .225). Power under ~θUBL is .927 and expected sample size is 335.0. For
~θUBl , power is .870 and expected sample size is 388.5. With further distortion, repre-
sented by ~θUBL = (.325, .325, .325, .625, 1, .625, .325, .325, .325) and
~θUBl = (.325, .325,
.625, 1, .625, .325, .325, .325, .325), performance to detect the signal on the leaf suffers further
but power for a signal on the limb is robust. Power under ~θUBL is then .924 and expected
sample size is 334.6. For ~θUBl the power is .792 and expected sample size is 389.4.
We also consider a decrease in the maximum effect. This could also be considered a
misspecification of δ4. The first case is when the decreased effect exists on a limb: for
~θDL = (.125, .225, .125, .625, .9, .625, .125, .125, .125) power is .805 and expected sample is
359.7. This is in keeping with the performance of the standard design, whose power is .790
and whose expected sample size is 381.8. When the depressed effect is on a leaf, the decay
in power is not so great. For ~θDl = (.125, .125, .625, .9, .625, .125, .125, .125, .125), the power
is .842 and the expected sample size is 387.6. This exceeds the performance of the standard
design.
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TABLE 4: ROBUSTNESS OF LIMB-LEAF DESIGN PERFORMANCE
Type of Response Curve/ Parameter Vector Power E(N)
Step Function (1)
~θS = (.125, .125, .125, .625, .625, .625, 1, 1, 1) .963 334.3
Plateau (1)
~θP = (0, .16, .33, .5, .66, .83, 1, 1, 1) .945 333.6
Monotone Increasing (1)
~θM = (0, .125, .250, .375, .500, .625, .750, .875, 1) .947 367.2
Bimodal (2)
~θBL = (.125, .225, .125, .625, 1, .625, .125, .125, .125) .925 335.2
~θBl = (.125, .225, .625, 1, .625, .125, .125, .125, .125) .885 388.7
~θBL = (.125, .325, .125, .625, 1, .625, .125, .125, .125) .926 332.9
~θBl = (.125, .325, .625, 1, .625, .125, .125, .125, .125) .847 389.9
Unimodal with Background (2)
~θUBL = (.225, .225, .225, .625, 1, .625, .225, .225, .225) .927 335.0
~θUBl = (.225, .225, .625, 1, .625, .225, .225, .225, .225) .870 388.5
~θUBL = (.325, .325, .325, .625, 1, .625, .325, .325, .325) .924 334.6
~θUBl = (.325, .325, .625, 1, .625, .325, .325, .325, .325) .792 389.4
Depressed Maximum (3)
~θDL = (.125, .125, .125, .625, .9, .625, .125, .125, .125) .805 359.7
~θDl = (.125, .125, .625, .9, .625, .125, .125, .125, .125) .842 387.6
Notes: (1) Power exceeds design power for these cases. (2) Power is unaffected when
the effect is on the limb. There is a decrease in power for an effect on the leaf as it be-
comes more difficult to identify the promising region. (3) The decrease in power for an
effect on a limb dose is in keeping with that of a standard design (see discussion). The
performance for an effect on the leaf dose is less impacted.
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8.2.3 Discussion and Conclusions
This study demonstrates the Limb-Leaf Design in a specific situation where the assumption
of a locatable effect in a nonmonotonic dose response curve is satisfied. A significant benefit
is seen over a standard seamless design of the TSE-type. In the chosen example with the
need to identify a dose having 70% or more of the target effect, the savings in risk adjusted
expected sample size over the standard design reaches 25%. The Limb-Leaf Design allocates
resources on an as needed basis rather than committing early to a thorough search.
Given that prior information can be imprecise, it is necessary to study the robustness
of the design under deviations from the assumed dose response curve and/or misspecifica-
tions of the parameters. The results are reassuring but not perfect. The standard cases of
Step Function, Monotone, and Plateau alternatives perform well, with greater power than
designed. Degradation of power is seen in the Bimodal case and in the case we labeled “Uni-
modal with a Background.” This degradation is only noticeable when the target effect is on
a leaf dose. The cause is misdirection of the design to explore the wrong area of the dose
response curve as it grows harder to identify the promising region based on the first stage
limb performance. Degradation of the power also occurs when the target effect is depressed.
This decline is either similar to that seen in the standard design, for a target effect on a
limb, or somewhat less, for a target effect on a leaf dose.
As seen in the Bimodal and Unimodal with Background cases, as δ1 grows in relation to δ2,
it becomes harder to resolve a region of promising effect in the first stage and the performance
begins to suffer. If such an alternative is anticipated by design, a large sample size could be
required that could negate the benefits of the limb-leaf strategy. In such a situation, one could
“front load” the Limb-Leaf Design by removing the constraint that n1 = n2L. For example,
with anticipated alternative ~θ = (.325, .325, .325, .325, .325, .325, .625, .625, 1), having δ1 =
.325 and δ2 = .625, leaf power of 90% and limb power exceeding 90% can be achieved with
n1 = 68, n2L = 42, n2l = 85, and a search strategy using ~a = (.2, .75, 1); Epi(N) is then 353.5.
The risk adjusted expected sample size for the optimized standard design in this situation
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is 368.2. On the other hand, “back loading” the Limb-Leaf Design is possible when the
assumed alternative would make second stage selection more difficult. Under an anticipated
Depressed Maximum alternative, with ~θ = (.125, .125, .125, .625, .9, .625, .125, .125, .125), the
choice n1 = 60, n2L = 80, and n2l = 160, and the search strategy using ~a = (.2, .656, .9)
results in Epi(N) = 403.5 and meets the desired power conditions. The risk adjusted expected
sample size of the optimized standard design for this situation exceeds 500. Other simulations
show that if one can allow a difference in power between the cases of an effect on a limb and
an effect on a leaf of up to 5 %, a smaller risk adjusted expected sample size can be achieved
than when the power must be more evenly balanced.
We conclude that the benefits of Limb-Leaf Designs make them attractive for situations
where their assumptions are acceptable. We suggest that adaptive exploration through a
limb-leaf strategy is one answer among many to calls for innovation in clinical trial design
by the FDA [44] and by specialists (such as Schoenfeld and Cudkowicz, [36]) for a diversity




Further work on Limb-Leaf Designs could take several directions. One is to explore the best
use of Limb-Leaf Designs within a drug development program. Enhancements to the design,
such as group sequential stopping boundaries and the ability to switch endpoints, could
be incorporated by applying known techniques. Statistically, the properties of point and
interval estimates derived from Limb-Leaf Designs could be investigated by known methods.
We would like to give a brief discussion of these directions.
The needs of a Limb-Leaf Design may call for changes in the standard drug development
plan. For instance, Phase I trials could be modified to collect preliminary data on efficacy
endpoints and to assess the assumptions of the Limb-Leaf Design. A comprehensive liter-
ature review, the use of animal studies, pharmacodynamic models, and the meta-analysis
of existing evidence on the drug of interest as well as related drugs could all contribute to
the study design process for a Limb-Leaf Design. The composition and operation of the
team that designs and conducts the study could be modified with a greater role and a more
integrated role for the statistician. This follows the recommendations by Rockhold [32].
The advantages of group sequential boundaries to stop early for efficacy or futility are
described by many authors, including O’Brien and Fleming [31]. In our case, the advantages
may be somewhat less because the criterion of distinguishing the desired effect from adjacent
promising effects may be more stringent than that of confirming the effect on the selected
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dose. Once the sample size is sufficient to allow correct selection with high probability
at the second interim analysis, very little additional sample size may be required for high
probability to confirm the effect of the selected dose. If needed, group sequential boundaries
could be constructed by one of two methods. The first would be, for each the hypothesis HD
(associated with the set of doses D), to generalize the cutoff cD to a sequence of c
1
D . . . c
I
D
according to an α spending function α(t) : 0 ≤ t ≤ 1. Adaptations could preserve the
conditional type 1 error rate at each interim analysis rather than the conditional type 1
error rate across all future analyses in order to maintain a correspondence with the original α
spending function. A second method would consider the first two (selection) stages of a Limb-
Leaf Design as their own study and to extract a multiplicity adjusted P -value for the effect
of the selected treatment. Further stages could stand independently and be combined with
the previous evidence using a prespecified group sequential combination rule as described by
Mu¨ler and Scha¨fer [29].
Selection at the first and second interim analyses may be based on outcomes other than
the primary endpoint. The resulting multiple testing procedure is conservative. An im-
provement could be made by taking account of the relationship between endpoints. The
correlation between score statistics for different endpoints can be estimated and the use of
the bivariate distribution can lead to a less conservative procedure. This was done by Stal-
lard and Todd [39] and their method could be applied to a Limb-Leaf Design with a change
of endpoint.
Estimation is important for regulatory and medical needs. An established estimation
method in selection studies uses bias adjusted estimates. The performance of these estimates
and the associated confidence regions in selection studies is studied by Stallard and Todd in
[40]. Similar results are likely in the case of Limb-Leaf Designs. Another method for interval
construction, the repeated confidence interval method discussed by Brannath, Posch, and
Bauer [7], may also be relevant.
83Appendix: Figures.
FIGURE 1: Comparison of Conditional Error Functions.














Note: The Conditional Error Function of a combination test represents the boundary between the
acceptance and rejection regions and provides insight into the robustness and efficiency of the asso-
ciated combination rule. The conditional error functions associated with the Maximum, Weighted,
and Horizontal rules under adaptation Plan 1 of Section 4.3 are graphed above. For discussion see
Section 4.3.
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FIGURE 2a: EXAMPLE PROFILES WITH LOCATABLE EFFECTS.
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